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ABSTRACT OF DISSERTATION 
FRAILTY IN PATIENTS UNDERGOING LEFT VENTRICULAR ASSIST 
DEVICE IMPLANTATION 
Heart failure is a progressive condition that affects over 5.7 million Americans 
and costs associated with heart failure account for 2-3 % of the national health care 
budget. The high rates of morbidity and mortality along with increased costs from 
readmissions associated with advanced heart failure have led to the exploration of 
advanced treatments such as left ventricular assist devices (LVADs). LVADS have 
demonstrated morbidity and mortality benefit but cost remains extensive with costs per 
quality-adjusted years > $400,000. With this in mind, it is important to identify those who 
are most likely to benefit from an LVAD to avoid unfavorable outcomes and cost. 
Although general guidelines and criteria for patient eligibility have been established, 
choosing patients for LVAD implantation remains challenging. A new focus on patient 
selection involves the presence of frailty. While frailty has been studied in the elderly 
population and in patients undergoing cardiac surgery, frailty in patients undergoing left 
ventricular assist device (LVAD) remains controversial. The purpose of this dissertation 
was to examine measures of frailty in patients undergoing LVAD implantation. The 
specific aims of this dissertation were to: (1) identify a feasible frailty measure in adults 
with end-stage heart failure who underwent LVAD implantation by testing the hypothesis 
that frailty would predict 30 day rehospitalization rates using Fried’s criteria, Short 
Physical Performance Battery test, handgrip strength, serum albumin and six minute walk 
test (2) Determine whether frailty measures improve 3 months post LVAD implantation 
(3) compare sensitivity of these three measures to change in frailty.
Surgical approaches, including heart transplantation and LVAD implantation, for 
patients with end-stage heart failure was discussed in this dissertation. Data from two 
subsets of participants who underwent LVADS at the University of Kentucky between 
2014 and 2017 were included in the analysis for this dissertation. In the first study, we 
found that none of the measures are good predictors of frailty in patients with advanced 
heart failure who undergo LVAD implantation. Handgrip was the only marker of frailty 
that predicted 30 day readmission but the relationship was a negative association. In the 
second study, six-minute walk and low serum albumin levels reflect short-term 
improvement in frailty. These simple measures may be used to determine those patients 
who are responsive to LVAD implantation. 
The findings of these studies filled some gaps in our understanding of markers of 
frailty in patients undergoing LVADs. We gained a better understanding of which 
markers of frailty are likely to improve in most people after LVAD implantation and thus 
frailty should not preclude candidate selection for an LVAD. Subsequently, more 
research is needed to investigate these markers and outcomes. 
KEYWORDS:  left ventricular assist device; frailty, six minute walk test, albumin, hand 
grip strength 
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Chapter One: Introduction 
Heart failure is a progressive condition that affects 5.7 million Americans with 
more than 670,000 new cases a year. Costs of heart failure care account for 2-3% of the 
national health care budget.- Heart failure readmissions remain a burden with re-
hospitalization rates of 20% at one month and 50% at 6 months.  Over 43% of patients 
diagnosed with heart failure are hospitalized at least five times or more within 5 years of 
being diagnosed. There has been very minimal improvement in survival with medical 
treatment, particularly for patients with end stage heart failure with 1 year mortality in 
such patients of 15-35%. 
The high rate of morbidity and mortality, and poor quality of life associated with 
heart failure has led to exploration of additional treatments for those with advanced heart 
failure that include left ventricular assist devices (LVADs). There is a morbidity and 
mortality benefit with use of LVADs, although the cost associated with their use is 
extensive.- In addition to fixed cost from the LVAD, which is greater than $100,000, 
LVADS may result in complications, such as bleeding and infection, that contribute to 
increased cost due to re-hospitalization, treatment and prolong hospitalization.  
 For the past decade, improvements have occurred in device technology, patient 
selection and postoperative management, which have led to decreased cost but despite 
these advances, costs per quality-adjusted years is still >$400,000. Iyengar et al examine 
the relationship between length of stay and cost and demonstrated that in the LVAD 
population, a 25% decrease in average length of postoperative stay was associated with a 
40% decrease in average costs.  They also reported that complications such as bleeding, 
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respiratory failure and infections after LVAD implant were associated with increased cost 
of $20,000-$50,000. 
In order to gain better insight into to the expenses associated with complications 
associated with LVAD implantation, a multidisciplinary team approach was incorporated. 
This additional focus not only examined risk factors associated with complications, 
which includes hypotension, inotrope requirements, obesity and RV dysfunction, but also 
included physical therapy and nutritional assessment. By providing more focus on patient 
education in regards to physical and nutritional needs and risk factors associated with 
complications, a reduction in cost associated with LVADs was noted. 
 With this in mind, it is important to investigate factors that could potentially 
decrease further cost and complications without compromising treatment outcomes. One 
possible way which expands on the study posed by Iyengar et al is to consider whether 
the patient meets criteria for frailty that could be addressed before or during 
hospitalization. Many elderly heart failure patients, especially those who are hospitalized, 
are frail. Frailty has been identified as an important prognostic marker for adverse 
outcomes including death, disability and re-hospitalization. - Thus, identifying patients 
with frailty while they are hospitalized may promote intervention to manage frailty and 
its consequences, thus decreasing cost. 
Frailty is a construct that includes assessment of physiological insults across 
many organ systems that result in increased vulnerability to physical and psychological 
stressors. -  While a few investigators have examined the relationship of frailty and 
outcomes of advanced heart failure patients, no one has examined the relationship 
between frailty and hospital length of stay and readmissions in patients who receive an 
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LVAD.-  The purpose of this dissertation is to determine markers of frailty in patients 
undergoing LVAD implantation and the association of pre-operative frailty with post-
operative frailty on length of stay and re-admissions and to determine whether the 
components of frailty are stable or whether they change after LVAD implantation. 
In the second, third and fourth chapters of this dissertation, I examine how end-
stage heart failure is treated with LVADs. In addition, I examine how frailty impacts 
length of stay, 30 day readmissions and if frailty improves 3 months after LVAD 
implantation. I also compare my proposed markers of frailty to an existing model to 
determine if the measurements are similar. The final chapter of the dissertation 
summarizes the findings of the previous chapters and bridges gaps in current research.  
End-Stage Heart Failure 
Heart failure currently affects more than 5.7 million Americans and more than 26 
million people worldwide and attributes to substantial costs of more than $30.7 billion 
annually.  It is estimated by 2030 that heart failure will affect more than 8 million adults 
in the United States and costs associated with heart failure will continue to increase to 
exceed more than $69.7 billion.,  A majority of cost are attributed to frequent 
hospitalizations as the disease progresses toward end-stage heart failure. More than 43% 
of patients are hospitalized more than 5 times within 5 years of being diagnosed. It is 
estimated that approximately 5-10% of patients with heart failure are end stage or stage D 
and have persistent symptoms despite guideline-directed medical therapy (GMDT) 
resulting in more frequent hospitalization.  Approximately 15-35% of patient with end 
stage heart failure have a1 year mortality.,  
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Once diagnosed with heart failure, patients are placed on GMDT in an attempt to 
not only provide symptom relief and prevent hospitalizations, but also improve mortality 
and decrease the risk of major cardiovascular events. As the disease continues to 
progress, more definitive treatments for end-stage heart failure should be considered. Due 
to disease severity, limited therapeutic options are available including inotropic support, 
cardiac transplantation or left ventricular assist device (LVAD).  
The American College of Cardiology/American Heart Association and the Heart 
Failure Society of America recommend continuous inotropic support for the treatment of 
advanced heart failure to patients who have failed GMDT in an attempt to improve 
quality of life and reduce symptom burden.- Inotropic support may be used to stabilize 
patients as a bridge to cardiac transplant or mechanical support, or discharge home.  
Patients initiated on inotropic support require close monitoring due to the potential of 
symptomatic hypotension, life-threatening arrhythmias or worsening renal dysfunction.  
While inotropic support may provide symptom relief, there is no mortality benefit 
and 1 year survival rate on inotropic support is approximately 10-15%.,  For patients who 
are discharged home on inotropic support, palliative care should be involved to assist 
with end of life care as they start to fail inotropic support. For those who are on inotropes 
as a bridge therapy, close monitoring for signs of deterioration is crucial for timing of 
surgical intervention.  
Definitive surgical intervention for end-stage heart failure includes ventricular 
assist device or cardiac transplantation. Heart transplant remains the preferred treatment 
of end-stage heart failure with an estimated survival rate of 90%. However, in the United 
States the number of people waiting for a heart transplant continues to increase and is 
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approximately 3,805 which is a 25% increase over the past decade. The number of 
donations remains stable around 3.5 per 1000 deaths and wait times continue to increase. 
Due to donor shortage, mortality on the heart transplant wait list is high with 
approximately 10% of patients dying per year while waiting for a heart transplant., ,  
LVADs are increasingly being utilized in patients with end stage heart failure to bridge 
patients to heart transplant and as destination therapy for those who are not transplant 
candidates.  
LVADs were originally designed as a bridge to cardiac transplants but have evolved 
to include destination therapy for treatment of end-stage heart failure in those who meet 
eligibility requirements.  The Randomized Evaluation of Mechanical Assistance for the 
Treatment of Congestive Heart Failure trial established the use of LVADs as a treatment 
for patients with end stage heart failure and reported a 48% reduction in death from any 
cause. LVADs have an estimated 1 year survival of 89% and over 68% report improvement 
in quality of life. Additionally, over 77% of patients implanted with LVAD report 
improvement in NYHA class., ,   
Left Ventricular Assist Device 
The rise in the healthcare budget and increased incidence and prevalence of heart 
failure has led to the exploration of advanced therapies for heart failure to improve 
treatment outcomes and decrease cost associated with this devastating disease. As heart 
failure progresses, the addition of continuous intravenous inotropic support, such as 
dobutamine and milrinone, may improve clinical outcomes, but is associated with a poor 
survival rate at 1 year of 10-30%. These patients have diminished functional status, poor 
quality of life and have frequent readmissions. Only a minority of patients are eligible for 
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heart transplantation, and of those, many will not receive a transplant because of the 
limited supply of donor hearts. This situation leaves a substantial number of patients with 
limited options. The addition of LVADs as an adjunct to traditional medical treatment for 
heart failure patients who require advanced therapies to improve long-term survival is 
gaining acceptance., , ,    
LVAD is a type of implantable mechanical circulatory support that assist the 
native left ventricle. It consists of internal and external components that work to increase 
cardiac output. The LVAD has an inflow cannula which is inserted into the left ventricle 
and connects to a pump, which is connected to an outflow cannula that attaches to the 
aorta. Blood is propelled by a rotor through the system into the aorta and systemic 
circulation. The pump also has a driveline, which connects the internal pump to an 
external power source. 
LVADs which were originally used as a bridge to heart transplantation are now 
approved as destination therapy in patients who cannot receive heart transplant or cannot 
wait for a heart transplant. Randomized clinical trials have noted a 48% risk reduction of 
death in LVAD patients compared to patients on medical therapy. In the USA, the 
incidence of LVAD implantations has increased from 2006 to 2010 from 206 to 1451 
while the number of heart transplants remains unchanged. According to the 2014 
ITERMACS registry 3500 continuous flow-LVADs (CF-LVADs) were implanted in 
2013, while the number of heart transplants remains around 2200 implants per year in the 
US. In addition, hospital cost associated with heart failure improved over the last 10 years 
as the number of LVAD implants increased with approximately $14,000 or 3.6% per 
patient.,   
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While the overall survival of patients on CF- LVADs has an increased at 1 year to 
85% (HeartMate II) and 92% at 6 months (HeartWare), the CF-LVAD is not without 
burden. Although the implantation of CF-LVAD is considered safe and effective, adverse 
events with CF-LVADs can lead to poor outcomes and re-hospitalization. The most 
common complications associated with second generation CF-LVAD include bleeding 
and infection. 
Gastrointestinal (GI) bleeding is the most common complication and cause of re-
hospitalization in patients with CF-LVAD. The incidence of GI bleeding in patient with 
CF-LVADs is between 18.9% and 22.3%. Risk factors for GI bleeding in patients with 
CF LVADs included older age (20.5 x greater risk of bleeding) and chronic renal 
insufficiency.-  
GI bleeds in patient with CF-LVADs stems from a combination of factors 
including anticoagulation, anti-platelet therapy, Von Willebrand disease, impaired 
platelet aggregation and formation of arteriovenous malformations in the GI tract.,  When 
CF-LVADs are implanted, a non-biological surface is placed in the body. Blood flows 
over this surface, which predisposes the blood to clotting. To reduce the incidence of 
clotting, there is a need for anticoagulation.  CF-LVADs require anticoagulation with 
warfarin, which increases risk of bleeding. Nearly all patients who experience GI 
bleeding have therapeutic or subtherapeutic INRs at the time of bleeding suggesting that 
antithrombotic therapy alone does not account for higher bleeding rate in patients with 
CF-LVADs., ,   
Physiological changes related to the lack of pulsatility also contribute to increased 
rate of GI bleeding in patients with CF-LVADs. Native hearts create pulsatility, which 
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results in pressure and flow changes. The human cells detect and adapt to these changes. 
Pulsatility results in shear and strain forces on the endothelium, smooth muscle and 
fibroblast cells in the circulation which in turn results in vasodilatation and vascular 
remodeling.- Without pulsatility, the normal processes do not occur. Instead there is a 
thinning of the vasculature, decreased bradykinin-dependent vascular relaxation. There is 
also increased vascular oxidative stress which results in degradation of vascular cell 
proliferation. This results in angiodysplasias, which attribute to approximately 55% of 
bleeding lesions in patients with CF-LVADs.-  
Acquired von Willebrand syndrome has also been noted to be a common cause of 
bleeding in patients with CF-LVADs. Von Willebrand factor is necessary for platelet 
aggregation. When the blood passes through the pump, shear stress disrupts multimers 
associated with factor VIII, which leads to acquired von Willebrand deficiency resulting 
in coagulopathy.-  
While the etiology of GI bleeding is found in over 70% of cases by upper 
endoscopy or capsule endoscopy, GI bleeding continues to be problematic in patients 
with CF- LVAD and treatment of GI bleeding is essential to lowering healthcare cost 
associated with readmissions. Few investigators have examined medications to assist with 
preventing or slowing GI bleeding in patients with CF-LVADs but all of these 
medications are still under investigation and attribute to significant costs. Additional 
factors that can decrease cost associated with GI bleeds need to be examined and studied.   
As the number of LVAD implants increase, complications of device related 
infection emerge. Approximately 17% of patients with LVADs develop infection within 
the 1st year post-implant and the risk increases to 33% and 45% at 3 and 5 years 
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respectively. One of the most common infections associated with LVADS is driveline 
infection with a rate of 7%, 20% and 29% at 1, 3 and 5 years respectively. Patients are at 
risk of developing driveline infection due to a percutaneous driveline that extends from 
the internal pump, out the skin, to an external energy source. Most driveline infections 
are at the driveline exit site and if untreated, travel up the driveline to the pump resulting 
in a pump pocket infection. Once a patient has a pump pocket infection, the risk of 
bacteremia and sepsis increase. As a result, patients are often hospitalized due to the 
complexity of medical care and require extensive, long-term antibiotic coverage and 70% 
require surgical revisions which results in substantial cost.- Infection associated with 
LVADs contributes to 41% of deaths.  
Due to the expense associated with readmissions, increased length of stay, 
morbidity and mortality associated with infection, researchers have focused on factors 
linked to increased risk of infection post-LVAD. Heart failure patients are already at 
higher risk of morbidity and mortality due to nutritional disorders, cachexia, and being 
overweight. These same co-morbidities are being examined in patients with LVADs. 
Nutritional factors such as low albumin are associated with increased post-surgical risk of 
infection and research has demonstrated that low albumin levels and BMI are 
independent predictors of readmission due to drivel line infection.,  Research regarding 
BMI is controversial. Some research supports that BMI is not a relevant factor in 
determining post-operative risk associated with infection while other studies support that 
overweight and obesity contribute to increased risk of infection post LVAD., , ,   
Readmissions due to these complications is common and results in a significant 
percentage of health care costs in this population. While the overall cost-effectiveness of 
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treatment with an LVAD continues to improve, 5 year cost is estimated at $360,000. To 
minimize expense associated with complications post VAD and re-hospitalization, it is 
necessary to investigate factors or ways to decrease cost. One such way is to focus on 
patient selection prior to LVAD implant. Patients with advanced heart failure already 
have a wide range of comorbidities that can lead to unplanned hospital readmissions and 
increased length of stay and this risk increases after LVAD implantation. These patients 
are at increased risk of poor baseline health status, function decline and decreased quality 
of life, all of which are predictors of mortality.,  While previous research has focused on 
reducing hospital cost and readmissions due to bleeding and infection, a new focus on 
patient selection prior LVAD implantation, which has extensively been studied in other 
populations, is frailty. 
Overview of Frailty 
Frailty is an evolving concept that is gaining interest in a variety of populations. 
Over 6 million people in the United States are frail and this number is believed to be 
underestimated. It is recognized as a prognostic indicator and is a risk factor for adverse 
clinical outcomes including mortality and prolonged hospitalization.- Approximately 45% 
of patients who are frail have a 1 year mortality rate. In addition frailty is also predictive 
of falls, institutionalization and is independently associated with post-operative 
complications.  
 Frailty is a complex syndrome that affects many organ systems as a result of 
stressors in the setting of a vulnerable state. Many suggestions have been proposed to 
define frailty, but no formal definition has been recognized due to the complexity of the 
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syndrome and inconsistencies in measurement. In this dissertation, I will define frailty in 
the following section.  
Frailty has extensively been studied in the community dwelling geriatric 
population, and more recently has been investigated in patients with cardiovascular 
disease and patients undergoing cardiac surgery. , , , Studies suggest that frailty exists in 
25%-50% of patients with cardiovascular disease, 7% of people age 65-75 years and 26% 
of people over the age of 75 years. Frailty occurs in 65-75% of patients with heart failure 
and is a significant predictor for frequent hospitalization. Patients who are frail have a 
65% higher hospitalization rate than non-frail patients. In addition, frailty in patients with 
cardiovascular disease have a 2 fold increase in mortality and women with coronary 
artery disease (CAD) are more likely to develop frailty.,  
Multiple studies have been examined to assess the prevalence of frailty in 
community dwelling older adults with cardiovascular disease. The Cardiovascular Health 
Study (CHS) (n=4735), Zutphen Elderly Men’s Study (n=420), Beaver Dam Eye Study 
(n=2962) and French 3 City Study and Health ABC study (n=3208) and Women’s Health 
and Aging Studies (n=670) all noted an association between frailty and cardiovascular 
abnormalities.,  Older community dwelling women were noted to be at higher risk of 
developing frailty compared to men and were more likely to develop CAD events. In 
addition, CAD and stroke were at highest risk of developing frailty and frailty was 
strongly predictive of long-term survival. 
Outside of community dwelling adults, there have been few studies examining the 
impact of frailty in older hospitalized adults. In a study by Purser et al, patients with 
cardiovascular disease admitted to the hospital were noted to be frail which was 
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measured by slow gait speed and have a fourfold increase in mortality over 6 months 
(n=309).,  Patients with heart failure are 54% more likely to be frail and frailty was more 
predictive of mortality than New York Heart Association Class. Another study by Lee et 
al focused on patients admitted after undergoing cardiac surgery noted that frailty was 
associated with a 43% increased risk of post-operative complications, length of 
hospitalization and inability to be discharged home. Frailty was also highly correlated 
with 30 day, 1 year and 2 year mortality due to the patients having a decreased ability to 
mobilize and ambulate which contributed to additional complications such as post-
operative pneumonia and re-intubation. Approximately 50% of patients in this study had 
frailty measured by gait speed.  
Frailty is also pertinent to the development and prognosis of patients with heart 
failure. The Health ABC study concluded that frailty correlated with a 30% higher risk of 
developing heart failure.,  Patients with heart failure who are frail have a higher 1 year 
mortality risk than those who are not frail (17% vs 5%) and have more hospitalizations 
(21% vs 13%) and impaired quality of life. In addition, patients with frailty had 
prolonged hospital length of stay. The CHS study supported previous findings that frailty 
in heart failure patients is associated with functional decline and increase risk of 
hospitalization. 
Frailty has also been studied in patients undergoing cardiac surgery to predict 
post-operative outcomes. The Frailty Assessment Before Cardiac Surgery (Frailty ABC) 
noted a 46% incidence of mortality in patients with slow gait speed compared to a 6% 
incidence in those with normal gait speed. Additional studies also noted that pre-operative 
frailty was associated with post-operative mortality at 30 days and 1 year.,  In addition, 
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frail patients were less likely to be discharged home and were more likely to need 
rehabilitation.  
To date, few investigators have examined frailty in patients who undergo LVAD 
implantation. Their findings have provided conflicting data (Table 1.1). Three 
investigators examined the association of frailty with an increased time to extubation. 
Only one group of investigators found a significant association between frailty and longer 
time to extubation. , - Five groups of investigators compared hospital length of stay, which 
found conflicting results. Prolonged length of stay was reported in 2 groups and no 
difference in hospital length of stay was noted in the remaining 3 groups., - Three 
investigators examined short term mortality (less than 30 days) and found no difference 
between frail and non-frail patients., ,   Additionally, seven groups of investigators 
examined long term mortality and only one reported increased mortality associated with 
frailty., , , - The most commonly used measurement tool for these studies was Fried’s 
phenotype. 
   Handgrip strength is a marker of frailty in other populations. A study by Chung 
et al noted that impaired handgrip strength correlated with global myopathy, higher 
postoperative complication rates and increased mortality following LVAD implantation. 
While this study did not examine frailty, Chung et al makes reference that measures of 
skeletal muscle function, such as handgrip strength, are part of the frailty phenotype and 
may have prognostic value in patients undergoing LVAD implantation.   
No studies have focused on interventions that slow or improve frailty in both the 
LVAD and non-LVAD population but some have focused on interventions that may 
improve physical function. Studenski et al  analyzed 9 large prospective studies and 
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found that for every 0.1 m/s increase in gait speed, there was a 10% improvement in 
survival in patients with heart failure. Maurer et al discuss that there were some 
improvements to physical function in patients 3 months post LVAD implantation but 
frailty itself was not reversed. It was suggested that to better assess improvements in 
frailty additional components such as nutritional support should be incorporated into the 
assessment. A study by Fiatarone et al attempted to expand on this by adding nutritional 
support to their program, which did support that a high intensity exercise training 
improved muscle strength and noted improvement in mobility and gait speed. However, 
even with nutritional intervention, the nutritional status remained compromised.   
Due to the implications of previous research and statistics, it is important to focus 
on ways to prevent or slow the progress of frailty. In order for this to be effective, one 
must first understand the variables that result in frailty. Due to the complexity of frailty, 
there is no standard definition, which makes it difficult to conceptualize. Various 
attempts have been made to try and operationalize and define frailty. This will be 
discussed in the following section. 
Defining Frailty: Conceptual Framework 
While it is well known that frailty is a predictor of poor prognosis, defining frailty 
has not been established. Even identifying criteria for frailty has been difficult due to the 
complexity of the syndrome. Most variables that affect frailty are commonly associated 
with other co-morbid conditions and aging which makes it difficult to distinguish 
between the attributes. Some conditions such as cardiovascular disease, stroke, 
depression, obesity and osteoarthritis, share the same characteristics as frailty leading to 
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the potential for misclassification. Disputes continue as to what criteria should be used to 
define frailty due to the relationship of frailty with aging, disability and chronic disease.  
Research proposes that frailty is caused by underlying processes separate from 
aging, but these processes have similar manifestations as other conditions as mentioned 
previously. Patients with frailty and other co-morbid conditions such as cardiovascular 
disease, arthritis, depression, obesity often have chronic low-grade inflammation. After a 
stressor event, there is further disruption of homeostasis, which results in a decline of 
status due to increased circulation of inflammatory markers. This results in a “cascade of 
events” in which musculoskeletal, nutritional and hormonal defects interplay resulting in 
further inflammatory and hormonal response causing further decline.,   This cycle 
continues resulting in changes to skeletal muscle, leading to profound muscle loss and 
impairs the body’s ability to maintain and repair itself, which promotes further decline in 
physical performance, mental status and malnutrition.,   While frailty may encompass the 
resulting components of this cycle such as malnutrition, loss of dependence, decreased 
gait, generalized weakness, weight loss, muscle loss and exhaustion it is difficult to 
discern frailty from other underlying conditions.,   This supports the importance of further 
defining and conceptualizing frailty for better understanding.  
The concept of frailty is complicated by the lack of a consistent definition. 
Several definitions of frailty are discussed in the literature. Some of the more frequently 
used definitions of frailty define frailty as a “state of increased vulnerability to adverse 
outcomes,” an age associated biological condition and a dynamic state affecting an 
individual who losses function and a geriatric syndrome due to a decline in physiological 
reserve., , ,  Frailty has become increasingly relevant due to increased risk for 
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decompensation, adverse events, complications, mortality and functional decline and 
finding ways to measure frailty is on the rise.,   
  Frailty is multi-factorial and includes deficits that accumulate throughout life. 
Frailty encompasses several attributes including skeletal muscle mass loss, decreased 
activity levels, poor endurance, decline in walking performance and decreased activities 
of daily living.,  Several measures of frailty have been examined but due to variability in 
definition, no standard measurement of frailty has been identified. Over 20 assessment 
tools have been developed to measure frailty and more than 70 variables have been 
examined in these models to assess frailty, yet there is no formally objective measure. 
These instruments share common core items including slowness, weakness and physical 
inactivity. 
The most common measurement of frailty in patients with heart failure is the 
frailty phenotype developed by Fried and colleagues (Table 1.1). The frailty phenotype 
defines frailty as the presence of 3 or more of the following 5 physical indicators: low 
physical activity, weakness (measured by hand grip strength), slow walking speed, 
unintentional weight loss (>10 lbs in 1 year) and self- reported exhaustion.,   The Fried 
scale has demonstrated to predict mortality and disability in community dwelling elders, 
patient with cardiovascular disease, patients with heart failure and patients undergoing 
cardiovascular surgery or procedures. Several modifications of the Fried scale have been 
widely used to assess frailty in several substrates of population with over 200 
modifications with physical activity and weight loss being modified most often., ,  
While the Fried score is one of the most widely used measurements, some of the 
individual components have been studied and are associated with frailty. Single item 
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measures appear to be sufficient at assessing frailty and are more practical. Gait speed is 
commonly used to measure frailty and is associated with a 3 fold increase in post-
operative mortality and morbidity for patient undergoing cardiac surgery. In addition, 
slow gait speed is associated with a 30% increase of hospitalizations in patients with 
heart failure.,  Gait speed alone was also the most accurate predictor of 6 month mortality 
in a study assessing frailty in patients with coronary artery disease.,  It is easily applicable 
without much time or cost and doesn’t rely on subjective questionnaires. The patients use 
little effort and walk comfortably.  
Poor grip strength is also predictive of frailty and is used often due to patients not 
being able to ambulate or being to deconditioned to perform other measures of frailty. 
Handgrip strength correlated with operative risk in patients undergoing cardio-surgery, as 
well as increased length of stay and was independently predictive of 30 year mortality.,  
Handgrip strength was also noted to be predictive of disability and functional decline 
over 25 years. 
Another common measurement of frailty in patients with cardiovascular disease, 
older adults and patients with heart failure is the Rockwood’s frailty index of multiple 
deficits, also known as the deficit index. Measuring frailty through the deficit index 
allows one to determine the severity of frailty through age associated health disorders 
such as symptoms, diseases, disabilities. The index is associated with negative health-
related outcomes including hospitalizations and mortality. This measurement is more 
commonly used in community dwelling elderly population due to the ease of use. In 
addition, the deficit index is more sensitive predictor of outcomes than Fried’s frailty 
phenotype  because it is a more sensitive measure of a patients vulnerability to stressors. 
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While it is comprehensive, administration of the assessment is time consuming which 
limits its use. Frailty is determined based on a calculated index. A Score 0.21 < FI < 0.45 
= frail and FI > 0.45 most frail. This concludes that the frailer person is the more 
vulnerable they are to adverse outcomes. 
The CHS scale and the MacArthur Study of Successful Aging (MSSA) are 
additional instruments used to measure frailty in patients undergoing cardiac surgery. The 
CHS scale includes the 5 items of Fried’s Criteria: gait speed, weakness measured by 
handgrip strength, physical inactivity measured by questionnaire, exhaustion measured 
by questionnaire and unintentional weight loss > 10 lbs in 1 year. If three or more items 
are positive, one is classified as frail. In addition, the CHS has several modifications 
some of which have been expanded to include cognitive impairment and mood 
disturbance. The MSSA also includes 5 items; cognitive impairment, self-reported 
weakness, anorexia, high IL-6 and high CRP. Four or more items are required to be 
deemed frail.  
The Short Physical Performance Battery (SPPB) test is an instrument for 
measuring physical performance in the aging population and has been used to measure 
frailty. This measurement of frailty has also been extensively examined in older adults 
with cardiovascular disease. The SPPB measures frailty by examining slowness, 
weakness and balance. Three timed physical performance tests are performed: gait speed, 
chair rises and tandem balance. Each is scored on a 0 to 4 scale and one is considered to 
be frail if they have a total score < 5 of 12.   
 The SPPB has been identified as one of the best physical performance tests to 
identify frail adults and is associated with disability and mortality. It has good  concurrent 
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validity when compared to other measures of frailty. Patients with lower SPPB score are 
more likely to be disabled and have a higher mortality rate or re-hospitalization rate over 
1 year. In addition, patients who had a score of 8 out of 12 had a significantly shorter 
length of hospital stay compared to the subgroup with a score of 4 or less.  
 Multiple attempts at defining and conceptualizing frailty have been attempted, but 
all populations are different and are affected by different variables, which makes it 
difficult to generalize one specific instrument to measure all populations. In addition, it is 
difficult to discern underlying conditions associated with co-morbid conditions and frailty 
itself. A systematic review of the literature on frailty led to exploration of a new 
conceptual framework to further define frailty in the LVAD population.  
This conceptual framework (Figure 1.1) incorporates the most important 
components of frailty in the LVAD population. A full understanding of the concept of 
frailty in this population is necessary to understand how it impacts health outcomes. 
Further definition of some of the variables of the concept were explored.  
Malnutrition and weight loss 
Patients with advanced chronic heart failure often experience progressive 
unintentional weight loss, as a result of decreased appetite and malabsorption due to 
gastro-intestinal congestion.  Unintentional weight loss (> 10 lbs in on year) has been 
shown to be associated with post-operative complications, prolonged hospitalization, 
decreased survival and greater burden of morbidity and mortality in patients with heart 
failure.,  Unintentional weight loss occurs in approximately 50 % of patient with heart 
failure and approximately 15% of heart failure patients are found to have cardiac 
cachexia.-  
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Cardiac cachexia is a multifactorial metabolic and inflammatory response 
associated with increased morbidity and mortality. Cachexia was a predictor of 18 month 
mortality in patients who had percutaneous coronary intervention. Cardiac cachexia 
occurs as a result of decreased absorption of nutrients through the gastrointestinal system 
and increase metabolic demands leading to a catabolic state resulting in muscle wasting 
which leads to further weight loss and malnutrition., ,  Inadequate nutrition is associated 
with poor outcomes, increases length of hospitalization and results in postoperative 
complications.,  Cardiac cachexia is a strong indicator for mortality in patients with heart 
failure and when combined with low peak oxygen consumption, it identifies patients at 
high risk of death. Some research supports more favorable outcomes with higher BMI 
and survival, but there is limited data on the effects of weight loss on survival. 
Due to the negative impact of cardiac cachexia and malnutrition on outcomes of 
patients with heart failure, measures of nutritional status are being examined. One such 
measure is by examining albumin levels. Low albumin levels < 2.5 mg/dl are associated 
with increased morbidity and mortality in patients who have had general cardiac surgery, 
as well as all cause mortality in older adults., ,  Hypoalbuminemia in heart failure patients 
is also being examined. In the heart failure population, low albumin is due to 
inflammatory stress, hepatic congestion and impaired protein syntheses. Albumin levels 
are associated with higher NT-proBNP levels and worse NYHA status. Low albumin 
levels decrease intravascular osmotic pressure of the capillary beds. This leads to loop 
diuretic resistance due to a decrease of albumin-loop diuretic binding capacity. The 
binding of albumin to diuretics is key for effective diuresis.  
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Additional research has examined the relationship of low albumin levels and 
BMI. Patients with serum albumin levels of less than 2.5 g/dl have an increased risk of 
death and post-operative bleeding.,  In combination with a low BMI less than 20, these 
patients were at increased risk of death, stroke and bleeding, while patients with BMI 
over 30 had increased risk of arrhythmias and infection. An additional study by Rapp-
Kesk also supported that patients with low BMI and low serum albumin levels were at 
increased risk of death and infection post cardiac surgery.  
Nutritional status has been studied in patient with heart failure through various 
screening tools such as the Mini Nutritional Assessment Short Form, Nutritional Risk 
Screening and the Prognostic Nutritional Index. These screening tools are complex and 
subjective and an easy and more objective form of measuring nutritional status, via serum 
albumin levels, is gaining acceptance.  Serum albumin levels are an easy and objective 
measure of nutritional status. As mentioned previously, serum albumin levels have been 
well studied in the general cardiac surgery population and are associated with poor 
outcomes and has also been studied as a predictor for survival in patient with heart 
failure., ,  More recently, limited studies have examined low albumin levels in the LVAD 
population. Low albumin levels (<2.5 mg/dl) are associated with morbidity and mortality 
after LVAD implant and decreased survival. However, one study noted that low albumin 
levels are corrected within six months after LVAD implantation. Further analysis of 
albumin is needed before conclusions can be made regarding postoperative outcomes in 
patients with LVADs.,  
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Strength 
Loss of muscle mass and changes in muscle metabolism are well known markers 
of frailty in patients with cardiovascular disease, coronary artery disease and cardiac 
surgery patients.,  In patients with heart failure, global myopathy results in decreased 
strength. Hand grip strength is a marker of frailty that has been correlated to outcomes 
and mortality in these populations. It is independently recognized as a predictor of 
mortality and functional decline. Several frailty scoring systems measure handgrip 
strength due to the ease of administration with minimal physical stress on patients. In 
addition, it is measured by a dynamometer, which is relatively inexpensive and can be 
tested in patients who are ambulatory and non-ambulatory. This is important for patients 
with advanced heart failure due to severity of their illness resulting in deconditioning and 
frequent hospitalizations. Most patients with advanced heart failure who are being 
considered for LVAD are weak and cannot tolerate testing that results in stress.  
While several studies in other populations have examined handgrip strength as a 
measure of frailty and how it relates to outcomes, few studies have examined hand grip 
strength as a measure of frailty in the LVAD population. Handgrip strength defined as at 
least 25% of body weight was associated with decreased survival and increased 
complications including bleeding and infection in patients undergoing LVAD 
implantation.,  While patients in this study were thought to have more physical limitations 
than patients in other studies, almost 1/3 of patients had noted improvement in handgrip 
strength 6 months after LVAD implantation.  
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Functional Capacity 
Deterioration in skeletal muscle associated with advanced heart failure is 
currently being studied. Changes in muscle fibers, decrease in type 1 fibers and increase 
in type 2 fibers, occurs as a result of the metabolic demands associated with cardiac 
cachexia, which results in a decline in functional capacity. In addition, these changes to 
the muscle structure result in changes to muscle mitochondrial and enzymatic capacity 
which are usually measured by VO2 max. Measuring peak oxygen consumption requires 
complicated and expensive equipment. Most studies to date that are examining frailty 
have assessed exercise capacity by measuring gait speed because it is a time and resource 
efficient prognostic indicator of mortality., It has been well studied in other populations 
and is associated with mortality, functional decline and increased operative risk.,  
However, gait speed does not measure VO2 max, which leads to the assumption that the 
6 minute walk test may be a more accurate predictor in patients with heart failure since it 
has been established as a measure of aerobic capacity. The 6MWT best correlates with 
maximal oxygen consumption compared to other measures and is easy to be 
administered, well tolerated by patients and reflects daily activities. Several studies have 
reported that the 6 MWT is a reliable measure of increased mortality and re-
hospitalization and is a strong indicator of poor prognosis in patients with heart failure.  
Studies in patients with heart failure have demonstrated that the 6 minute walk 
test is a valid measurement of functional capacity and have found an association with 
mortality and outcomes., ,  Walking less than 300 meters is a predictor of increased 
morbidity and mortality. Mortality was 3.5 times higher if subjects walked less than 350 
meters than those walking over 450 meters. The 6 min walk test is a feasible measure in 
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patients with heart failure and is already incorporated into routine care. The 6MWT also 
encompasses may domains of physical function, which are part of the frailty phenotype. 
A comparison between the 6 minute walk test and frailty using gait speed demonstrated a 
high correlation between the two measures in patients with heart failure. Another recent 
study reported that the 6 minute walk test was the strongest predictor of post- LVAD 
survival. Further research is needed to understand how to best assist frail patients to 
improved post LVAD implant.       
This analysis of the concept of frailty provides a framework for the important 
variables that contribute to frailty in the LVAD population and it was used in the studies 
reported in this dissertation. It is important for the purpose of this dissertation that the 
concept of frailty be efficiently defined, as there has been inconsistency in the literature 
and has not been well studied in the LVAD population. 
Gaps 
This dissertation will fill some of the gaps in the literature by increasing our 
understanding of how variables of nutrition, functional status, and strength result in 
frailty. Many assessment tools and measurements of frailty have been well studied in 
other populations but are not well known in the LVAD population. Part of the issue may 
be that patients undergoing LVAD are critically ill and may not be able to participate in 
some of the previously reported measures.  
In exploring the influence of the different measurements of frailty, more research 
is needed to examine and compare previously reported measures of frailty post VAD. 
Current literature by Maurer et al notes that handgrip strength and gait speed improved 6 
months post LVAD implant but weight loss is resistant to change which contradicts 
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previously reported research supporting that LVAD implantation results in weight gain. 
The study was small and did not provide meaningful results of frailty on length of stay 
and survival. Most studies have also focused on older adults (> 60) which limits 
generalizability of the previous studies. With LVADs increasing as destination therapy 
and bridge for transplant, a wider age range needs to be examined. In addition, while 
some assessment tools examine physical capabilities and nutrition as markers or frailty, 
further studies are needed to assess if interventions are beneficial in slowing or 
preventing frailty in these areas prior to procedures and surgery. Additional research is 
needed to assess whether any markers of frailty will predict or effect current standards for 
patient selection.  
Summary of subsequent chapters 
The impact of frailty on outcomes and rehospitalization in patients who receive 
LVADs was studied in this dissertation. I explored markers of frailty in this population. 
The variables discussed in this conceptual framework were used to guide the study, 
designs, data collection, data analysis and interpretation of the results.  
Chapter two was the discussion of surgical approaches to patients with end stage 
heart failure. This chapter was important because it discussed the pathophysiology of end 
stage heart failure and surgical approaches including heart transplantation and LVAD as 
treatment options for this population. This is important because it provides the 
background on how patients are selected for LVADs. Patients undergoing LVAD 
implantation have to meet criteria to qualify for candidacy but additional conditions such 
as frailty should also be considered to select patients who will benefit from implantation. 
Patients with LVADs are at increased risk of complications post LVAD, rehospitalization 
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and increased health care cost associated with these complications and it is important to 
gain a better understanding to improve patient selection for LVADs, reduce readmissions, 
reduce hospital cost and decrease hospital length of stay. 
Chapter three was the report of a study in which markers of frailty included in the 
proposed conceptual framework to define frailty was compared to previously reported 
markers of frailty which include Fried’s criteria, SPPB, 6MWT, Albumin and handgrip 
strength.  This study was important because it established if markers of frailty included in 
the proposed conceptual framework are appropriate markers of frailty in patient 
undergoing LVAD implantation. 
Chapter four was the report of a study conducted to determine whether frailty 
improved 3 months post LVAD. This is important because only one study to my 
knowledge have examined frailty post LVAD. A study by Maurer et al reported that 
frailty measured by the Fried frailty criteria, decreased in approximately half of patients 6 
months after receiving LVAD support. This study was important as it lays the ground for 
future research to assess how improvements in frailty impact readmissions, length of stay, 
complications post LVAD and cost post LVAD.  
Chapter five is the integration of the previous chapters. It provides further 
explanation of the link between the different variables of frailty and how they impact 
outcomes. The comparison between variables and outcomes was further explored.    
 
 
 
27 
 
Table 1.1: Frailty in LVADs 
Author Sample 
Size (n) 
Outcome 
Measurement 
Results Frailty 
Measurement 
Joseph 2017 75 -Time to 
extubation 
-Hospital LOS 
-Short Term 
Mortality 
-Long Term 
Mortality 
-Significant 
-Significant 
-Not 
significant 
 
-Not 
significant 
Fried Score 
Jha 2017 77 -Time to 
extubation 
-Hospital LOS 
-Long Term 
Mortality 
-Not 
significant 
-Not 
significant 
-Not 
significant 
Fried Score 
Mangehelli 2014 45 -Time to 
extubation 
-Short Term 
Mortality 
-Not 
significant 
-Not 
significant 
Fried Score 
Cooper 2017 2469 -Hospital LOS 
-Long Term 
Mortality 
-Significant 
-Not 
significant 
Provider 
assessed frailty 
and gait speed 
Heberton 2016 100 -Hospital LOS 
-Long Term 
Mortality 
-Not 
significant 
-Not 
significant 
Sarcopenia 
Dunlay 2014 99 -Hospital LOS 
-Long Term 
Mortality  
-Not 
significant 
-Significant 
Deficit Index > 
0.25 
Sundararajan 
2016 
154 -Short Term 
Mortality 
-Not 
significant 
Cachexia > 10 
kg weight loss or 
absolute BMI < 
20 
Fan 2017 50 Long-Term 
Mortality 
-Not 
Significant 
Fried Score 
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Table 1.2: Review of most common assessment tools for frailty  
Frailty Measure Criteria Determinants of Frailty 
Fried Criteria 5 Criteria; Unintentional 
weight loss of > 10 lbs in 
one year; Weakness 
measured by handgrip 
strength; Exhaustion that 
was self-reported Slowness 
measure by gait speed; Low 
physical activity self-
reported  
Positive 3 of 5 phenotypic 
criteria 
Deficit Index Cognitive status; Mood and 
motivation; 
Communication; Mobility; 
Balance, Bowel function, 
bladder function; ADLs; 
Needing help from nutrition 
or social resources; Number 
of comorbidities divided by 
2 
Has at least 30 assessed 
health variables 
 
FI = Deficits 
   n- missing values 
 
FI < 0.10 nonfrail 
     0.21 < FI < 0.45 Frail 
     FI > 0.45 most frail 
Gait Speed Time to walk 5 meters Time to walk 5 meter > 6 
seconds 
Handgrip  Handgrip measured with 
hand dynamometer 
HGS < 85% normal 
Short Physical 
Performance Battery 
Gait speed; Time taken to 
stand from sitting in a chair 
5 times without using arms; 
Tandem balance  
Each is scored on a 0 to 4 
scale: frail if they have a 
total score < 5 of 12 
Comprehensive 
Assessment of Frailty 
Handgrip Strength; Gait 
Speed; Activity level; 
Standing balance; Body 
control 
HGS < 85% normal; > 6 
seconds to walk 5 meters; 
Questionnaire regarding 
IADLs to calculate weekly 
kcal expenditure; Standing 
balance assessed by 
amount of time individuals 
could stand with both feet 
together, semi-tandem, full 
tandem and make a 360 
degree turn; Body control 
assess by time individuals 
could get up and down 
from chair 3 times, pick up 
a pen from floor and put on 
and remove a jacket 
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Table 1.2, continued 
Frailty Staging System Disability; Mobility 
disability; Cognitive 
impairment; Visual 
Impairment; Hearing 
impairment; Total urinary 
incontinence 
Disability: loss of > 1 
BADL, Mobility 
inability to do 
housework, Cognitive 
by mini-mental status 
exam; 0-1 impairments 
= class 1 
2-3 impairments = class 
2 
4-7 impairments = class 
3 
Canadian Study of Health 
and Aging Clinical Frailty 
Scale 
Very fit (regular exercise); 
Well (no active disease); 
Well (with treated disease); 
Vulnerable (complain of 
being slowed by disease); 
Mildly frail (limited 
dependence for ADLs); 
Moderately frail (limited 
dependence for ADLs and 
IADLS); Severely frail 
(complete dependence for 
ADLs and IADLs or 
terminally ill) 
Assess by a physician, 
nurse, physiotherapist 
and occupational 
therapist 
Cardiovascular Health Study 5 items: gait speed, 
weakness measured by 
handgrip strength, physical 
inactivity measured by 
questionnaire, exhaustion 
measured by questionnaire 
and unintentional weight 
loss > 10 lbs in 1 year 
Presence of 3 or more 
MacArthur Study of 
Successful Aging 
5 items; cognitive 
impairment, self-reported 
weakness, anorexia, high IL-
6 and high CRP.  
4 or more items deem 
frailty 
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Figure 1.1: Conceptual framework of frailty in patients with heart failure 
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Chapter Two: Surgical Approaches in Heart Failure 
Introduction 
Heart failure is a progressive condition that continues to rise in both incidence and 
prevalence accounting for more than 2-3% of the national health care budget.-  Despite 
improvements in treatment for end stage heart failure, the costs per quality-adjusted years 
is still greater than $400,000. The high rate of morbidity and mortality associated with 
advanced heart failure has led to exploration of additional treatments, which include 
surgical interventions to improve outcomes.-  This article will focus on the most common 
surgical interventions that have demonstrated improvement in morbidity and mortality for 
patients with heart failure. 
Epidemiology of HF 
The epidemiology of heart failure has been extensively studied for the past several 
decades with a large contribution of literature stemming from the Framingham Heart 
Study. Major findings in the 1980’s noted that heart failure increases with age, is higher 
in men that women. In addition, hypertension, coronary artery disease and diabetes 
mellitus are associated with increased risk of heart failure. In the 1980’s the prevalence of 
heart failure was 24 per 1,000 in men and 25 per 1,000 in women with a median survival 
time of 1.7 years in men and 3.2 years in women. 
Longitudinal analysis of the Framingham Study noted in the 1990’s that heart 
failure continued to rise in incidence and prevalence affecting about 1% of persons in 
their 50’s with progressive increases to about 10% of persons in their 80’s. The incidence 
also increased with age from 0.2% in persons 45 to 54 years to 4% in those 85 to 94 
years. Mortality was noted to be around 37% within 2 years of diagnosis., , ,   
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Continued analysis of epidemiologic data from the Framingham Study in the 
2000s further supported the burden of heart failure effecting over 5 million Americans 
with more than 550,000 new cases a year.,    Median survival was noted to be similar for 
men and women as in the 1990’s with a 5 year survival rate of 25% of men and 38% of 
women. Hypertension was noted to have the largest impact on heart failure, followed by 
myocardial infarction, valvular heart disease and diabetes., ,  
At present, heart failure affects more than 5.7 million Americans with more than 
670,000 new cases a year. Readmissions related to heart failure continue to remain a 
burden with rates of 20% at one month and 50% at 6 months with more than 43% of 
patients being hospitalized more than five times or more within 5 years of being 
diagnosed.  Heart failure related admissions account for 56.7% of all heart failure 
episodes with heart failure, with heart failure being the most common reason for 
hospitalization in adults aged 85 years and older and the second most common for adults 
aged 65- 84 years.- Approximately 15 to 35% of patient with end stage heart failure have 
a 1 year mortality. Hypertension and diabetes remain the top co-morbidities linked to the 
high prevalence of heart failure. ,  
Pathophysiology of systolic HF 
Heart Failure is defined as “a complex clinical syndrome that results from any 
structural or functional impairment of ventricular filling or ejection of blood”. This 
condition can ultimately lead to decreased exercise tolerance as well as symptoms of 
dyspnea at rest and/or exertion as well as fatigue and edema with variable severity. 
However, premise of heart failure physiology is increased intracardiac filling pressures, 
which is further explained in the following section. 
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Although there are two basic verities of heart failure, systolic as well as diastolic, 
this article focuses on systolic heart failure. Systolic heart failure whether treated 
according to guideline directed approach or not, ultimately leads to advancement of 
myocardial dysfunction with end-organs being affected, which brings up the concept of 
advanced heart failure. This entity is associated with refractory heart failure symptoms 
despite medical therapy as well as persistently elevated intracardiac filling pressures, 
inability to exercise as well as recurrent hospitalizations, which in turn is associated with 
increased mortality.  At this stage there are further options in treatment of heart failure 
such as inotropic support but inevitably surgical approach such as heart transplant as well 
as mechanical circulatory support. 
Strength of myocardial contraction has been shown to be related to the preload 
and thus the stretch of the fibers, which was first described by Otto Frank in 19th 
Century. This finding was elegantly confirmed a century later by Ernest Starling and 
colleagues where they have shown that increasing venous return and subsequent filling of 
heart chambers increased stroke volume. Thus a principal described by “the ability of the 
heart to change its force of contraction and therefore stroke volume in response to 
changes in venous return and subsequent chamber filling pressure” came to be known as 
Frank–starling principle. This is illustrated in Figure 2.1.               
Note the myocardium does not operate on the single Frank-Starling curve but 
rather its function as defined by multiple curves, as noted in Figure 2.2. These curves 
represent myocardial physiology based on its afterload as well as inotropic state as 
illustrated in Figure 2.2.  
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In order to improve the understanding of heart failure pathophysiology, it is 
important to understand frank starling curve, its principal of preload and how this 
correlates with intracardiac filling pressures and thus the concept of pressure volume 
loops. 
Looking at the Frank Starling curve, we can visualize the effects of increased 
preload in the form of left ventricular end-diastolic pressure (LVEDP) on the stroke 
volume. In a normal functioning heart the higher the LVEDP the higher the stroke 
volume with the curve theoretically not reaching its plateau as illustrated by Figure 2.1. 
In contrast, increased inotropy increases the slope of this line, making the myocardium 
more responsive and sensitive to preload with higher rate of stroke volume increased to 
the amount of preload increase as denoted by line B in Figure 2.2. Decreased inotropy, as 
in heart failure, appears to reach a plateau point of the curve at lower LVEDP, as 
represented by line C in Figure 2.2. 
To further visualize this principle, looking at pressure-volume loops becomes 
evident when venous return is increased, there is increased filling of the ventricle leading 
to an increase in end-diastolic volume (see Figure 2.3). If the ventricle now contracts at 
this increased preload the ventricle empties to the same end-systolic volume, thereby 
increasing its stroke volume, which is defined as end-diastolic minus end-systolic 
volume, provided that the afterload and inotropy are held constant. The increased stroke 
volume is displayed as an increase in the width of the pressure-volume loop. The normal 
ventricle, therefore, is capable of increasing its stroke volume to match physiological 
increases in venous return. This is not, however, the case for ventricles that are in failure. 
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In a failing heart and thus systolic dysfunction, there is evidence of downward and 
rightward shift of the Frank-Starling curve indicating loss of inotropy with resultant 
increase in left ventricle (LV) filling pressures. Initially there are multiple compensatory 
mechanisms in place to maintain stroke volume such as increased preload associated with 
neurohormonal upregulation and retention of Sodium leading to increased blood volume 
and thus increased filling pressures. Subsequently, these compensatory mechanisms 
result in chamber remodeling manifested by dilatation, which initially is in essence 
another compensatory phenomenon. This remodeling ultimately leads to decreased stroke 
volume and persistently elevated filling pressures and volume overload. These 
physiologic phenomena are illustrated in Figure 2.4. 
Principle of treating advanced heart failure 
The premise of treating heart failure is through control of congestion and thus 
preload as it has been shown that the predominant majority of symptoms and recurrent 
hospitalizations in heart failure patients are related to congestive exacerbation. In 
addition, an important concept in treating heart failure is through controlling afterload. 
This in turn can be achieved through neurohormonal blockade, which ultimately leads to 
decrease in intracardiac filling pressures. - The strategy of achieving neurohormonal 
blockade through medical therapy by utilizing the combination of angiotensin-converting 
enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB) with beta-blockers 
(BBs) as well as more recently angiotensin receptor–neprilysin inhibitor, have reached a 
Class I recommendation by the ACCF/AHA/HFSA.  
Luckily for those patients refractory or intolerant to guideline directed medical 
therapy, clinicians are now able to either replace the organ completely or support it with 
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implantable pumps. Replacing the organ improves the physiology drastically but holding 
true to the hemodynamic principle of heart failure the premise of treatment is to offload 
the heart decreasing intracardiac filling pressures through decreasing volume overload 
and improving the Frank-Starling forces such that it restores the pressure-volume loop 
position to the right, with concomitant improvement in stroke volume.   
Surgical Options 
Heart Transplant 
Despite advances in pharmacological as well as device therapy for chronic 
systolic heart failure, long-term morbidity and mortality remain unacceptably high. Five-
year mortality rate for patients with advanced heart failure is about 80% and thus further 
surgical approaches are necessary. One of those options and a gold standard treatment of 
advanced end-stage systolic heart failure is heart transplant. The fundamental indication 
for heart transplantation is poor quality of life as well as rapidly progressive physiology 
such as cardiogenic shock. 
Since the first orthotropic, inter-human heart transplant performed on December, 
3rd, 1967, at the Groote Schuur Hospital, in Cape Town, South Africa by Dr. Christian 
Neethling Barnard, great progress has been made. By end of 1968, 102 transplants were 
made in 17 countries and 52 centers. Only a third of these patients lived longer than three 
months.  It was not until 1980 with the dictation of cyclosporine, borrowed from renal 
transplant, that ultimate successful progress resulted in improved survival. To date, 
worldwide, about 3,500 heart transplants are performed annually. The vast majority of 
these are performed in the United States (2,000–2,300 annually) with an average 1 year 
survival rate of 90% with conditional half-life of 13.2 years. , ,  Heart transplant remains 
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to gold standard of advanced heart failure treatment for carefully selected patients. Box 1 
summarizes indications and contraindications for heart transplant.  
Surgical Considerations 
 
Orthotopic placement (organ placed in the anatomically original position) is the 
most commonly utilized placement of donor heart during surgery. There are two main 
techniques of anastomosing the recipient vasculature/structures to the donor heart: 
Bicaval as well as Biatrial techniques. Biatrial technique represents the most widely 
utilized approach to orthotropic heart transplant although this really depends on the 
transplant surgeon. Figure 2.5. 
Medical Considerations 
 
As noted in Figure 2.6, early graft failure over the first year is the most common 
cause of post transplant complications, including death. Graft failure downtrends with the 
first year primarily due to acute rejection while infectious complications associated with 
aggressive immunosuppression begins to take the stage during that time period. 
Ultimately resurgence of graft failure as well as concomitant cardiac allograft 
vasculopathy in addition to malignancy predominate long-term outcomes. 
Mechanical Circulatory Support 
Even though over the last 5 decades, heart transplantation has been the goal 
standard of care for carefully selected patients with end-stage heart disease, challenges 
continue to exist in this patient population. These challenges include complications 
associated with post-transplant care, but more importantly increasing number of potential 
recipient’s compared to the number of donor organs. Approximately 117,000 people need 
a lifesaving organ. Every 10 minutes someone is listed for transplantation and every 22 
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minutes someone dies while waiting for an organ. Because of this limiting factor, there 
has been increase in technological advances in order to be able to keep patients with end-
stage, advanced heart failure alive in order to ultimately offer them the gold standard of 
care. This technology being mechanical circulatory support, both short as well as long 
term. 
Interest in mechanical circulatory support (MCS) dates back to 1950’s during the 
time of development of cardiopulmonary bypass and open-heart surgery. The first 
successful implantation of a left ventricular assist device was completed in 1966 by Dr. 
DeBakey. A paracorporeal (external) circuit was able to provide mechanical support for 
10 days after the surgery. The lack of heart donors and contraindications to heart 
transplantation further stimulated the necessity for development of this technology. The 
first successful long-term implantation of an artificial LVAD was conducted in 1988 by 
Dr. William F. Bernhard of Boston Children's Hospital Medical Center.  
Initially pulsatile pumps were the standard of care given the thought that 
pulsatility is a necessary physiologic phenomenon. Both Randomized Evaluation of 
Mechanical Assistance for the Treatment of Congestive Heart Failure (REMATCH) and 
Investigation of Non-Transplant Eligible Patients Who Are Inotrope Dependent 
(INTrEPID) trials evaluated the role of pulsatile pumps in patients with advanced heart 
failure who were ineligible for heart transplant and noted 48% reduction in mortality 
compared with optimal medical therapy.,  The caveat and ultimately demise of pulsatile 
pumps was their durability. Having a device which durability reaches about 24 months 
could only serve as a prolonged bridge to transplant for patients who were too sick and 
thus required implementation of mechanical circulatory support in order to improve end-
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organ function and finally be placed on heart transplant list. And thus how about the 
patients who were not transplant candidates to begin with? Further endeavors with other 
devices gave rise of continuous-flow pumps. In 1987 in a pediatric patient shed some 
light in this regard when was implanted with a variation of continuous flow device as 
bridge to transplant. Dr. Frazier, in his case report states that this procedure “prompted us 
to speculate about broader application of nonpulsatile flow, to the development of fully 
implantable devices for long-term cardiovascular support of the terminal heart disease 
patient….The potential for long-term benefit lies in meeting the requirements of the 
circulatory system with a nonpulsatile pump”. At the same time interests for more 
durable devices has led to HeartMateII pump (a continuous-flow LVAD), replacing 
pulsatile technology after a study showed that continuous flow LVADs improve survival 
from disabling stroke and device failure as compared its predecessor (Heartmate XVE). 
Currently all devices on the market are continuous-flow pumps based on axial or 
centrifugal mechanism (See Figure 2.7). The axial-flow rotary pump consists of a 
rotating, screw-like propeller within a tube housing. The energy from the rotating element 
increases blood pressure and flow. The centrifugal pump with spinning blades captures 
and throws fluid forwards, which results in essentially pulseless physiology, depending 
on the residual left ventricular function. , 
Because temporary devices such as extracorporeal membrane oxygenation 
(ECMO) will be discussed elsewhere in this issue, this section will focus primarily on 
durable devices, namely LVADs as well as briefly discuss total artificial heart 
technology. LVADs unload the left ventricle and thus, because of the fact that blood is 
withdrawn directly from the left atrium (LA)/LV (considering there is no mitral stenosis), 
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pulmonary capillary wedge pressure (PCWP) and LV EDP decrease. This is shown by 
the Pressure-Volume (PV) loop left-ward as noted in Figure 2.8A. It should be noted that 
although it appears that stroke volume decreases even though there is significant left 
ventricular unloading as noted by the pressure volume loop, at the same time, arterial 
pressure increases as noted in Figure 2.8B. Although peak LV pressure and arterial 
pressure become increasingly dissociated compared to systemic, arterial blood pressure 
significantly increased and thus ultimately improving end organ perfusion often resulting 
in reversal of end-organ dysfunction. Figure 2.7B; Table 2.1. 
Four major indications for LVAD implantation exist: 
1. Bridge to transplantation (BTT),
2. Destination therapy (DT),
3. Bridge to recovery, and
4. Bridge to decision.
Indications and Contraindications for LVAD implantation are listed in Box 2. 
Bridge to transplantation remains the most common indication for implantation of 
LVADs. As mentioned earlier, due to the growing population of patients with advanced 
HF and stagnant numbers of donor organs, improved durability of the newer devices 
offers select patients increased survival and improvement of quality of life. This 
ultimately may let those patients remain candidates for transplant later down the line. 
Alternatively, destination therapy is offered to particularly selected patients with 
advanced HF who are not candidates for heart transplantation (Figure 2.9). 
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Temporary Options 
Temporary Options are listed in Table 2.2. 
Durable Options 
There are basically two types of devices used: para-corporeal (percutaneous 
ventricular assist device [PVAD]) and totally implantable (LAVDs or biventricular assist 
devices (BiVADs)) (Table 2.3). 
Total Artificial Heart 
The first successful implantation of total artificial heart which led to subsequent heart 
transplantation was performed in 1969. Subsequent successful implantations did not 
occur until beginning of 1980. Since that time there are many models she had been 
implanted but only one remains to be the most commonly utilized; SynCardiaTM TAH 
(SynCardia Systems, Inc., Tuscon, AZ, USA) Figure 2.10. This particular device is 
intracorporeal, pneumatically driven biventricular system, which completely replaces the 
failing heart. The use of TAH as a bridge to transplant has demonstrated a 79% survival 
to transplantation vs. 46% in patients not receiving a TAH in a small observational 
prospective study. Box 3 summarizes indications and contraindications for TAH 
implantation. 
Surgical considerations 
Because of the fact that human body generates a significant amount of scar tissue 
around the device, reentry for future heart transplantation becomes significantly more 
difficult. For this purpose the device itself as well as proximal vasculature are covered by 
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a Gore-Tex material in order to facilitate future reentry and minimize necessity for 
dissecting the structures.
Medical considerations 
Most recent analysis of INTERMACS registry reveals that about 80% of people 
are alive one year. Another analysis shows that survival to transplantation was 68.3% 
with strokes occurring in 7.9% of the population.
Post implant management revolves around proper anticoagulation as well as 
management of end organ dysfunction. The most common organs involved are liver 
kidneys with renal dysfunction being related to lack of natriuretic peptides (ANP and 
BNP). Level of post-operative end organ dysfunction is dependent on severity of 
decompensated state prior to implantation. 
Conclusion 
Heart failure continues to increase in incidence and prevalence despite 
pharmacological therapy and additional therapies such as cardiac resynchronization 
therapy and remains the most common cause of hospitalization. Heart failure is 
associated with poor quality of life and has an overall 1 year mortality rate of 20%. Due 
to the morbidity, mortality and costs associated with heart failure surgical advances are 
becoming more widely accepted.  
Although heart transplantation remains the gold standard, organ availability 
remains a major limitation. Due to the persistent donor shortage and increasing number of 
patient with advanced heart failure, mechanical circulatory support is gaining acceptance 
and can be used as a bridge to heart transplant for those eligible or as destination therapy. 
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The current strategy for the management of advanced heart failure with reduced ejection 
fraction (HFrEF) patients is to initially screen for heart transplant, with destination 
therapy ventricular assist device considered as secondary treatment for those who do not 
qualify for heart transplant. Regardless of which option is decided upon, the benefits of 
heart transplantation or ventricular assist devices outweigh those of pharmacological 
treatment of heart failure alone. Heart transplantation and ventricular devices improve 
symptoms and survival in advanced heart failure with a 1 year survival of 90% compared 
and should be considered in those who qualify.  
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Table 2.1. INTERMACS Profiles 
Level Symptoms Signs and Hemodynamics Need for LVAD 
1 "crash and burn" Critical cardiogenic shock, Within hours 
2 "sliding on inotropes" 
Progressive decline on inotropic 
support Within days 
3 "dependent stability" Stable but inotropic dependent 
Elective over weeks 
to months 
4 "frequent flyer" 
Resting symptoms although remains 
home on oral therapy with frequent 
hospitalizations. 
Variable urgency, 
dependent on 
nutrition and organ 
function 
5 Housebound Exertion intolerant 
Variable urgency, 
dependent on 
nutrition and organ 
function 
6 "walking wounded" 
Exertion limited to symptoms, 
although still responding to oral 
guideline-directed medical  therapy 
Variable urgency, 
dependent on 
nutrition and organ 
function 
7 
Advanced 
NYHA III 
symptoms 
NYHA class II or III, responding to 
oral guideline-directed medical 
therapy. 
Not currently 
indicated 
Abbreviation: NYHA, New York Heart Association 
Table 2.2. Temporary Devices: 
Device Mechanism Duration 
IABP Counterpulsation Days 
Impella Axial Flow Days 
ECMO Continuous Flow Days to weeks 
Centrimag Centrifugal Weeks 
Tandem Heart Centrifugal Days 
Abbreviations: ECMO, extracorporeal membrane oxygenation; IABP; intra-aortic 
balloon pump. 
45 
Table 2.3. Durable Devices: 
Device Mechanism Indications 
HeartMate II Axial Flow BTT, DT 
HeartMate III Centrifugal flow BTT 
HeartWare Centrifugal flow BTT, DT 
TAH Pulsatile BTT 
Abbreviations: BTT, bridge to transplant; DT, destination therapy; TAH, total artificial 
heart. 
Figure 2.1. Effects of Preload on Left Ventricular Filling Pressures and Ventricular 
Function: Frank-Starling Principle 
Abbreviations: LVEDP: Left Ventricular End Diastolic Pressure, SV: Stroke Volume. 
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Figure 2.2. Frank-Starling graph to show effects of inotrope on stroke volume relative to 
left ventricular filling pressures 
A) normal contractility B) increased contractility C) Decrease contractility
47 
Figure 2.3. Pressure-volume loop as it relates to increased preload (venous return) and 
left ventricular function (stroke volume). 
Abbreviations: EDP: End Diastolic Pressure, SBP: Systolic Blood Pressure, DBP: 
Diastolic Blood Pressure, AoV: Aortic Valve, LAP: Left Atrial Pressure, SV: 
Stroke Volume. 
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Figure 2.4. Pressure-Volume loop representing results of heart failure 
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Box 1
Indications for Heart Transplant: 
- Significant life, limiting heart failure:
o Persistent NYHA class III or IV symptoms despite maximal guideline
directed medical therapy.
o decreased exercise tolerance (peak VO2≤ 14mL/kg/min for patients not on
beta blockers and peak VO2≤ 12mL/kg/min for patients on beta blockers).
- Recurrent life-threatening LV arrhythmias despite optimized medical
antiarrhythmic therapy.
- Refractory cardiogenic shock requiring mechanical circulatory support  (LVAD,
TAH).
- Cardiogenic shock requiring continuous parenteral inotropic therapy.
- End-stage congenital heart patient with heart failure.
- Refractory angina despite maximal medical therapy and not amenable to
percutaneous or surgical revascularization.
- Severe hypertrophic or restrictive cardiomyopathy with end-stage heart failure
symptoms.
- Severe cardiac allograft vasculopathy in transplanted patients with evidence of
graft failure.
Contraindications for Heart Transplant:
- Age > 70 years old
- BMI > 35 kg/m
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- TPG > 15 mmHg, PVR > 5 Wood units or pulmonary artery pressure > 60 mmHg
with one of the above or the inability to achieve PVR < 2.5 Wood units with
vasodilator or inotropic therapy
- Primary Lung disease with impaired pulmonary function tests (FEV1 < 40% or
predicted, FVC < 50% or normal DL < 40%)
- Uncontrolled diabetes (HgbA1C > 7.5%)
- eGFR < 30
- Hepatic Cirrhosis
- Severe peripheral vascular disease not amenable to revascularization
- Active infections except LVAD related infections (HIV, Hepatitis B and Hepatitis
C)
- Active drug use: must be abstinent 6 months
- Non-compliance or lack of caregiver or social support
- Dementia or mental retardation
Abbreviations: BMI body mass index, TPG transpulmonary gradient, PVR pulmonary 
vascular resistance, FEV forced expiratory volume, FVC forced vital capacity, DLCO 
lung diffusion capacity, HbA1C glycosylated hemoglobin, mmol millimoles, mol moles, 
eGFR estimated glomerular filtration rate, mg milligrams, dl deciliters, HIV human 
immunodeficiency virus, TB tuberculosis 
(Data From Mehra MR, Canter CE, Hannan MM, et al. The 2016 International Society 
for Heart Lung Transplantation listing criteria for heart transplantation: a 10-year update. 
J Heart Lung Transplant 2016;35(!):1-23. 
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Figure 2.5. (A, B) Two different approaches for anastomosis during orthotropic heart 
transplant. 
A                        B 
      Biatrial Technique   Bicaval Technique 
IVC: Inferior Vena Cava, SVC Superior Vena Cava, PA Pulmonary Artery 
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Figure 2.6. Relative incidence of leading causes of death for adult heart transplants 
(deaths: January 2009–June 2016). CAV, cardiac allograft vasculopathy; CMV, 
cytomegalovirus; PTLD, post- transplant lymphoproliferative disorder. 
(From Kirlkin JK, Pagani FD, Kormos RL, et al. Eighth annual INTERMACS report: 
special focus on framing the impact of adverse events. J Heart Lung Transplant 
2017;36(10): 1080-6: with permission). 
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Figure 2.7. The mechanism of axial (eg, HeartMate II) versus centrifugal (HeartWare, 
HeartMate III) pump hemodynamics. 
 (From Lim HS, Howell N, & Ranasinghe A. The physiology of continuous-flow left 
ventricular assist devices. J Card Fail. 2017;23(2):170; with permission.) 
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Box 2
Indications for mechanical support: 
• Severe symptomatic heart failure despite optimal medical therapy
• Left Ventricular Ejection Fraction (LVEF) that is less than or equal to 25 percent.
• Exercise VO2 that is less than or equal to 12 ml/kg/min
• Continuous intravenous inotropes or IABP therapy to prevent symptomatic
hypotension, decreasing renal function or worsening pulmonary congestion.
Contraindications for mechanical support: 
• blood clotting disorders
• severe cirrhotic liver disease
• severe lung disease
• other co-morbid conditions  that result in < 1 year survival
(Data From Miller LW, Guglin M. Patient selection for ventricular assist devices: a 
moving target. J Am Coll Cardiol. 2013;61(12):1209-21.  
55 
Figure 2.8. Flow-dependent changes of the pressure-volume loop         
(A) Flow-dependent changes of the pressure-volume loop with LV-to-aortic pumping.
The loop becomes triangular and shifts progressively leftward (indicating increasing
degrees of LV unloading). Corresponding LV and aortic pressure waveforms at baseline
(B), 4.5 l/min (C), 6.0 l/min (D) and 7.5 l/min (E). With increased flow, there are greater
degrees of LV unloading and uncoupling between aortic and peak LV pressure
generation. CGS, cardiogenic shock.
(From Burkhoff D, Sayer G, Doshi D, et al. Hemodynamics of mechanical circulatory
support. J Am Coll Cardiol 2015;66-2671; with permission)
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Figure 2.9. Types of LVAD device 
(A) Axial Flow Device  (B) Centrifugal Device RA, right atrium; RV, right
ventricle
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Figure 2.10. Total artificial heart
(A) Gore-tex (Gore Medical, Flagstaff, AZ) sheets are sewn into the pericardial well
with a few 4-0 prolene sutures. After coming off bypass, and hemostasis is achieved,
the sheets can be wrapped around the ventricles to prevent harm on reentry. (B)
Percutaneous lines exit 6-8 cm from left subcostal margin.
(From  Morris RJ. The Syncardia total artificial heart; implantation technique. Oper
Tech Thorac Cardiovasc Surg 2012;17(@):164; with permission).
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Box 3: 
Indications: 
- Patients who are heart transplant candidates with severe biventricular failure and
imminent risk of death (INTERMACS profiles 1 and 2) in setting where suitable
donor is not available.
- Bridge to transplant in patients in need of re-transplantation experiencing graft
failure not responding to conventional therapy: Severe and diffuse coronary artery
vasculopathy.
- Patient’s with infiltrative or hypertrophic cardiomyopathy and associated low
output failure versus cardiogenic shock. Knees are patients not amenable to left
ventricular systolic devices
- Patient’s who experienced ventricular tachycardia storm or malignant arrhythmias
despite multiple ablations and medical therapy.
Contraindications: 
- Patients for ultimately not deemed to be transplant candidates
(Data From Arabia F. Total artificial heart. In: Kobashigawa JA, editor. Clinical guide to 
heart transplantation. Cham, Switzerland: Springer; 2017. P. 227-236.) 
Copyright © Candice Harvey Falls 2019 
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Chapter Three: Markers of Frailty in Patients Undergoing Left Ventricular Assist 
Device Implantation 
Abstract 
Background:  Frailty has been linked to adverse clinical outcomes, disability, 
increased hospital length of stay (LOS), readmissions and increased mortality. Several 
markers of frailty are associated with aging and other co-morbid conditions leading to 
uncertainty about their applicability to patients undergoing evaluation for Left 
Ventricular Assist Device (LVAD) implantation. The purpose of the study was to identify 
a feasible frailty measure in adults with end-stage HF who underwent LVAD 
implantation. In order to determine the best marker of frailty in LVAD patients, we tested 
the hypothesis that frailty would predict 30 day rehospitalization rates using Fried’s 
criteria, SPPB, handgrip strength, serum albumin and 6MWT in patients undergoing 
LVAD implantation.   
Methods:  A total of 23 patients were recruited and enrolled between January 
2015 and May 2016. This was an observational cohort study in which Fried’s criteria, 
SPPB, handgrip strength, serum albumin levels, and 6MWT were measured prior to 
LVAD implantation. Hospital readmissions was measured to examine the relationship 
between measures of frailty and 30-day rehospitalization rates.   
Results:  A total of 23 patients met eligibility criteria and were included in the 
analysis. Patients were labeled as frail or non-frail for each measurement of frailty. The 
vast majority of patients were labeled as frail. All patients were frail as measured by self-
reported exhaustion. Albumin, low physical activity and 6MWT were similar with 
approximately 91% of patients being measured as frail. Fried’s criteria labeled 87% as 
frail followed by gait speed (69.6%), Chair sit to stand (69.6%), Weight loss (65.2%), 
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Short Performance Physical Battery (60.9%) and Balance (56.5%).  Handgrip was least 
likely to measure one as frail (52.2%). During the 30-day follow-up period, 7 patients 
were readmitted to the hospital. Handgrip strength and 6MWT were the only two frailty 
indicators differed between those who were readmitted and not readmitted within 30-
days. Handgrip strength was the only marker predictive of hospital readmission and it had 
a negative association. Compared to those who were not frail, frail patients by handgrip 
criteria were 93.4% less likely to be admitted (p = 0.033). 
Conclusion:  Changes associated with the disease process of patients with end 
stage heart failure undergoing LVAD implantation makes it difficult to identify markers 
of frailty in this population. The findings of our study indicate that none of the markers 
are good predictors of frailty in patients with advanced heart failure with LVADs because 
they all identify a vast majority of the patients as frail.  
Introduction 
Chronic heart failure is a devastating and progressive condition affecting over 5.7 
million Americans, and demands enormous resources which together account for 2-3% of 
the national health care budget.- The number of adults with heart failure is expected to 
exceed 8 million and the annual costs is expected to increase from $30.7 billion to $69.7 
billion by 2030. Readmission rates remain a burden with approximately 50% of all 
patients being readmitted within six months and 25% being readmitted within 30 days.  
As heart failure progresses and becomes advanced, morbidity and mortality increase even 
further. 
The high rate of morbidity and mortality combined with increased costs for 
readmissions associated with advanced heart failure has led to the development of 
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advanced treatments such as implantable left ventricular assist devices (LVADs). While 
the use of LVADS is associated with a significant reduction in morbidity and mortality 
among patients with advanced heart failure compared to medical treatment alone, the 
costs associated with this technology remain high with an estimated cost per quality-
adjusted years of over > $400,000. Moreover, despite advances in technology, 
complications associated with LVADs such as infection, bleeding and stroke remain 
high. Minimizing complications in this population is essential to reducing 
rehospitalization rates and healthcare costs. It is important to identify those who are most 
likely to benefit from an LVAD and also identify those who are most likely to have 
complications associated with LVAD implantation. General guidelines and criteria for 
patient eligibility have been established and include the following: 1) severe symptomatic 
end-stage heart failure despite optimal medical therapy; 2) left ventricular ejection 
fraction (LVEF) less than or equal to 25 percent; 3) exercise VO2 less than or equal to 12 
ml/kg/min; and 4) continuous intravenous inotropes or intra-aortic balloon pump therapy 
to prevent symptomatic hypotension, decreasing renal function or worsening pulmonary 
congestion.,  Choosing patients for LVAD remains a challenge because these patients are 
often deconditioned and unstable due to the progression of their disease with a high risk 
of adverse events after cardiac surgery., Additionally, the overall physical condition of 
the patient is an important consideration particularly with respect to the capacity of the 
patient to participate in their own physical rehabilitation following LVAD implantation. 
Consequently, the concept of frailty has emerged as an important factor for appropriate 
patient selection.  
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Frailty is defined as an increased vulnerability due to age or physical condition 
because of decline in physiological reserves or function that compromises the ability of 
the patient to adjust to acute stressors.,  In the Cardiovascular Health Study, frailty was 
defined according to Fried’s Criteria: 1) poor grip strength; 2) slow gait; 3) low level of 
physical activity; 4) low energy or self-reported exhaustion; and 5) unintentional weight 
loss. Meeting a minimum of 3 criteria was defined as frail. 
Frailty has been linked to adverse clinical outcomes, disability, increased hospital 
length of stay (LOS), readmissions and increased mortality., , ,  Frailty has been studied in 
the elderly population and in patients undergoing cardiac surgery but not well studied in 
patients undergoing LVAD implantation. , ,  Fried’s criteria is the most commonly used 
measurement of frailty in patients with LVADs. Several components of Fried’s frailty 
score including decreased gait speed, self-reported exhaustion, low physical activity and 
weight loss are associated with aging and other co-morbid conditions leading to 
uncertainty about their applicability to patients undergoing evaluation for LVAD 
implantation. 
Another commonly used validated measure of frailty is the short physical 
performance battery test (SPPB). The SPPB assesses gait speed, balance and lower 
extremity muscle strength to identify those who are frail. The SPPB has been well studied 
in other populations including those with heart failure and identifies patients who are at 
high risk for progressive disability, increased hospital length of stay and mortality.,  The 
SPPB has not been used in patients with end-stage heart failure undergoing evaluation for 
LVAD implantation. 
63 
 
While Fried’s criteria and the SPPB are common measures of frailty, they are  
complicated to administer because they include multiple components with different 
modes of assessment. Identifying a more suitable measure of frailty that is feasible and 
sensitive in patients with LVADs is essential. Single markers of frailty may be a better 
indicator of frailty in this population., ,  Clinical evidence from the heart failure literature 
suggest that handgrip strength, albumin and six minute walk distance improve after 
LVAD placement, therefore these markers may be good measurements of frailty for this 
population.,  
Handgrip strength is a simple and effective measure of frailty. Assessing handgrip 
strength prior to LVAD implantation may aid in determining LVAD candidacy, as 
reduced handgrip strength identifies those at risk for increased LOS following LVAD 
implantation. Reduced handgrip strength is a predictor of reduced survival after VAD 
implantation, in addition to post-operative outcomes including bleeding and infection. 
Thus, handgrip strength may be a good individual marker for frailty in LVAD patients. 
Serum albumin is an indicator of disease severity in patients with heart failure and 
has been shown to be associated with increased mortality and morbidity.,  Up to 49% of 
patients with heart failure have hypoalbuminemia and serum albumin is an inexpensive 
marker recently proposed for the identification of patients with heart failure at risk of 
adverse outcomes.  In patients with LVADs, pre-implantation albumin was identified as a 
indicator of 3 month mortality post LVAD implantation and is associated with prolonged 
hospitalization in patients undergoing LVAD implantation.,   In addition, post-
implantation normalization of albumin levels is associated with improved survival.    
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Based in these findings, serum albumin may be a good single marker of frailty in LVAD 
patients.  
The Six Minute Walk Test (6MWT) is associated with frailty and predicts 
mortality in older patients with heart failure.  Furthermore, changes in 6MWT distance 
predict rehospitalizations. In patients with LVADs, the 6MWT is associated with 
functional decline and patients walking less than 300 meters have increased mortality. 
The 6MWT is feasible for patients with acute heart failure and can be used to assess 
baseline status and response to therapy, and thus might be a good single marker for frailty 
in LVAD patients. 
It is anticipated that identification of frailty in patients would enhance patient 
selection for LVAD implantation and potentially identify patients whose frailty is likely 
to reverse following successful implantation of LVAD. The purpose of the study was to 
identify a feasible frailty measure in adults with end-stage HF who underwent LVAD 
implantation. In order to determine the best marker of frailty in LVAD patients, we tested 
the hypothesis that frailty would predict 30 day rehospitalization rates using Fried’s 
criteria, SPPB, handgrip strength, serum albumin and 6MWT, in patients undergoing 
LVAD implantation.   
Methods 
Study design  
This was an observational cohort study conducted at a major academic medical 
center in which Fried’s criteria, SPPB, handgrip strength, serum albumin levels, and 
6MWT were measured prior to LVAD implantation. Hospital readmissions were 
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measured to examine the relationship between measures of frailty and 30-day 
rehospitalization rates.   
Sample and setting 
After receiving Institutional Review Board approval for the study, a total of 23 
patients were recruited and enrolled between January 2015 and May 2016 from a hospital 
associated with a major academic health center. Eligible participants were patients with a 
diagnosis of end-stage heart failure with reduced ejection fraction < 25% who were 
classified as New York Heart Association (NHYA) Class IV and who were scheduled to 
undergo LVAD implantation. All eligible patients during the enrollment time period 
agreed to participate and provided signed informed consent. Patients who could not 
complete the physical tests (n = 1) or who died before discharge (n = 1) were not eligible 
for the study.  
Measurement of variables 
These variables were measured in the patient’s room prior to LVAD implantation. 
All data were collected within 1 week prior to implantation. 
Fried’s Criteria 
Fried’s Criteria includes the following domains: 1) self-reported exhaustion; 2) 
physical activity; 3) weight loss; 4) strength; and 5) gait speed.  
Self reported exhaustion was measured by asking the patient the following 2 
questions from the Center for Epidemiologic Studies Depression Scale (CES-D): How 
often in the past week did you feel like everything you did was an effort and how often in 
the past week did you feel like you could not get up and going? Answers were 
categorized into 2 groups: Often (> 3 days) or not often (0-2 days). Those who answered 
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often were labeled as frail. The CES-D scale is the most common instrument used in the 
Fried’s criteria to examine self-reported exhaustion. 
Low physical activity was measured by asking the patient a single question to 
identify self-reported physical activity:  Over the past week (even if it was not a typical 
week), how much time did you exercise or were you physically active (included both 
exercise and your usual activities of daily living)? The answers were categorized into (1) 
None; (2) Less than 30 minutes/week; (3) 30-60 minutes/week; (4) More than 60 
minutes/week. More than 60 minutes a week was defined as being physically active, less 
than 60 minutes was defined as having low physical activity. The single-item question 
that was used was easy to complete and construct and validity have previously been 
established and have been used in several previous populations including patients with 
heart failure.  
 Weight loss was self-reported by asking the patient if they had ≥ 10 pound weight 
loss in the prior year. This is the most commonly utilized way of measuring weight loss 
for Fried’s criteria. ,   
 Strength was measured using handgrip strength, which is associated with 
increased mortality, bleeding and infection after LVAD implantation.  It was measured in 
the dominant hand using a Jamar Hydraulic Hand Dynamometer  (JLW Instruments, 
Chicago, IL), which is an accessible, widely used device. Handgrip strength was 
measured by a nurse practitioner who was trained by an exercise physiologist. Patients 
were asked to perform a maximal isometric contraction for 5 seconds with their dominant 
hand three times with a 30 second rest period between each contraction. Strength was 
defined as the average of the 3 contractions. Patients whose handgrip was less than 25 % 
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of their body weight in kilograms were labeled as frail. Those with a handgrip strength 
greater than 25% of their body weight in kilograms were labeled as non-frail.  
 Gait speed was measured as follows by the nurse practitioner. A cone was placed 
at the starting point and at the end point with a distance of 4 meters measured by a tape 
measure in between the starting and end point. Gait speed was measured with a stop 
watch and was defined as the time required for the participant to walk from the beginning 
to the end.  Gait speed is identified as a predictor of mortality and morbidity in patients 
undergoing cardiac surgery and has been identified as a frailty indicator in patients with 
advanced heart failure.,  
Short performance battery test 
The short physical performance battery test (SPPB) was used to measure lower 
extremity functional ability. The SPPB was conducted by a physical therapist. The SPPB 
is used to evaluate frailty using a series of three physical performance tests (gait speed, 
chair rises and tandem balance). Gait speed was measured as described above. Chair 
raises were conducted in the participant’s room. The participant was asked to go from 
sitting to standing position with arms were folded across chest 5 times as quickly as 
possible without stopping and was timed. Tandem balance was measured with feet 
positioned in 3 different positions (feet together, semi tandem with the heel of one foot 
placed by the big toe of the other foot and full tandem with feet directly in front of each 
other). The participant was asked to stand in each position for 10 seconds and was 
allowed to use arms, bend knees or move their body to maintain balance. Each tandem 
position was scored with a range of 0 to 4 (0= couldn’t perform, 1 = needed assistance to 
perform, 2 = performed with great difficulty by themselves, 3 = performed with some 
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discomfort, 4 = performed without difficulty or discomfort). After each tandem position 
was scored, the three measures were added together for a total score that ranged from 0 
(worst performance) to 12 (best performance).  Patients were classified as frail (SPPB 
score < 6), borderline frail (SPPB score 7-9) or non-frail (SPPB score ≥ 10). The SPPB 
has been shown to have predictive validity for mortality, increased hospitalization and 
disability in older adults.,    
Serum Albumin 
Hypoalbuminemia is a prognostic indicator in patients with heart failure and is 
associated with increased mortality and unfavorable outcomes.,  Serum albumin levels 
(g/dl) were measured by standard laboratory techniques. Serum albumin levels were 
collected at the time of the patients pre-operative routine laboratory work on the day of 
surgery and analyzed in the clinical laboratory at the hospital. Patient were categorized 
according to serum albumin level (frail < 3.5 g/dl and as non-frail > 3.5 g/dl).  
Six minute walk test 
The 6MWT has been identified as an important outcome measure of functional 
capacity in people with severe heart failure and is a marker of frailty. The 6MWT is safe, 
easy to administer and has been found to be reliable predictor of post-LVAD mortality. A 
nurse practitioner or physical therapist instructed the patients to walk for 6 minutes down 
a hallway free of obstacles at a pace at which they felt comfortable. Patients were 
permitted to use a walker or cane if needed and rest breaks were permitted, although time 
recording does not stop with any break.  The hospital hallway was marked in 1 meter 
increments and the total distance in meters walked in 6 minutes was recorded. Patients 
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walking less than 300 meters were classified as frail. Those walking greater than 300 
meters were classified as non-frail.  
Sociodemographic and Clinical Variables 
Gender, age, marital status, body mass index, comorbidities, and heart failure 
etiology (ischemic vs non-ischemic) were obtained from the medical record. Comorbidity 
data included diabetes, coronary artery disease and chronic kidney disease.  
Hospital Readmission 
 Hospital readmission data was obtained from the medical record. Time to hospital 
readmission was defined as time from date of discharge to the date of rehospitalization 
for any cause.  
Data analysis 
Demographic and clinical characteristics were reported using frequencies and 
percentages for categorical variables and mean ± standard deviation for continuous 
variables. Frequencies were used to determine frailty for each measure. Chi-square 
analysis was used to determine if the measures of frailty were predictive of 30 day. All 
analysis was conducted using SPSS software.  
Results 
A total of 23 patients met eligibility criteria and were included in the analysis. 
Patient characteristics are presented in Table 3.1. The average age of patients was 59 ± 9 
years.  Almost all participants were male and married. The primary etiology of heart 
failure for this population was ischemic cardiomyopathy. Over two-thirds of the patients 
had coronary artery disease and over half of the patients had diabetes mellitus.  Chronic 
kidney disease was prevalent in nearly half of the patients. 
70 
 
Patients were labeled as frail or non-frail for each measurement of frailty which is 
presented in Table 3.2. All patients were frail as measured by self-reported exhaustion. 
Albumin, low physical activity and 6MWT were similar with approximately 91% of 
patients being measured as frail. Handgrip was least likely to measure one as frail. 
 During the 30-day follow-up period, 7 patients were readmitted to the hospital. 
Median hospital length of stay was 19 days and median length of stay in the intensive 
care unit was 8 days. The most common cause for readmission was acute heart failure 
symptoms (n = 6). Only two frailty indicators differed between those who were 
readmitted and not readmitted within 30-days. These were handgrip strength and 6MWT. 
Of those admitted within 30 days of discharge, 14.3% were frail by handgrip criteria, 
while of those not admitted, 68.8% were frail by handgrip criteria.  Of those admitted 
within 30 days of discharge, 71.4% were frail by 6MWT criteria, while of those not 
admitted, 100% were frail by 6MWT criteria.  (Table 3.3). With the exception of 
handgrip strength, none of the criteria were predictive of hospital readmission (Table 
3.4). Compared to those who were not frail, frail patients by handgrip criteria were 93.4% 
less likely to be admitted (p = 0.033). 
Discussion 
The study demonstrated several indicators of frailty in patients with advanced 
heart failure undergoing LVAD implantation and which measurements were predictive of 
30 day re-hospitalization. The findings of our study indicate that measures of frailty that 
contain multiple components such as Fried’s criteria and SPPB, and measures that are 
single markers such as handgrip, 6MWT and albumin are not good predictors of frailty in 
patients with advanced heart failure with LVADs.  
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We found that nearly 87% of patients with advanced heart failure undergoing 
LVAD implantation were frail according to Fried’s criteria and 85% of those patients 
were readmitted within 30 days. While the Fried’s criteria is the most commonly used 
measurement of frailty in patients with HF and those with LVAD’s, it has been suggested 
that Fried’s criteria may not be applicable in patients with advanced heart failure 
undergoing LVAD implantation. The Fried criteria was originally developed to define 
frailty in a population of ambulatory adults. Due to the progression of disease and 
inflammatory response leading to deconditioning and debilitation, these measurements 
may not accurately reflect frailty in patients with advanced heart failure undergoing 
LVAD implantation.  
Some criteria such as self-reported exhaustion, self-reported physical activity, and 
weight loss may not be accurate in this population. Weight loss may be masked by 
volume overload in the setting of end-stage HF leading to inaccurate assessment of 
weight loss in the past year. Most patients with end-stage heart failure are not able to 
perform activity of daily living and have limited ambulation due to symptoms associated 
with heart failure including fatigue, shortness of breath and weakness. Therefore, self-
reported exhaustion and self-reported physical activity may not accurately reflect frailty, 
but may be only associated with disease progression of heart failure. 
The SPPB has been identified as a frailty indicator in patients with advanced heart 
failure and are predictive of outcomes. However, this was not found in our study. The 
SPPB is sensitive to the physiological decline associated with aging and is influenced by 
cognition and motivation which play a role in determining prognosis in frail patients with 
HF. The SPPB integrates the effects of physiological decline, malnutrition and 
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comorbidities. However, the SPPB is influence by severity of illness and symptoms and 
may not be feasible for many hospitalized patients.  By comparing individual components 
of this integration will allow for the possibility of markers of frailty that are easier to 
administer.  
One component of the SPBB and Fried’s criteria is gait speed. Our study did not 
support the findings of other investigators.,  Gait speed in patients with advanced heart 
failure undergoing LVAD implantation was not predictive of readmission and identified 
frailty in about two-thirds of the patients. Gait speed has been identified as a single 
measure of frailty and was found to be predictive of 6 month mortality when compared to 
Fried’s criteria in other populations.,  It is a preferred measure of frailty compared to 
SPPB and Fried’s criteria because it is quick to administer and practical and provides 
useful prognostic information.,  However, its applicability to patients undergoing LVAD 
implantation may be limited. There is a significant minority of patients who are not 
ambulatory or are unable to perform the activity. Alternative measures such as handgrip 
strength may be more feasible in this population. 
Handgrip was not a good measurement of frailty based on our findings. It 
identified few patients as frail. This contradicts other studies that support handgrip 
strength as a good predictor of frailty.,  To my knowledge no studies have examined 
length of stay to handgrip strength or prediction of handgrip strength to 30 day 
readmission. Our study found that handgrip strength was the only measure that predicted 
30 day readmission but the relationship was a negative association. For those who were 
frail by handgrip strength, they were more likely to not be admitted. The wide confidence 
interval indicates that this is not a precise measurement which may due to the small 
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sample size. Handgrip has been linked to increased length of stay when examined as part 
of Fried’s criteria in relation to outcomes and hospitalization.  
Measures such as gait speed, and 6MWT mainly use lower extremity strength to assess 
functional ability, handgrip strength is performed with minimal exertion using upper 
body strength, which could account for the difference of frailty classification.    
Post-LVAD implantation 6MWT has been examined and is associated with 
increased mortality.  It has been validated to measure functional capacity and outcomes in 
heart failure, but its utility in patients with LVADs in the context of frailty is unknown. 
The 6MWT identified over 90% of our patients as frail and is not a good measure of 
frailty in patients with advanced HF undergoing LVAD implantation. This is the only 
study to examine the 6MWT as an indicator of frailty in comparison to multiple other 
measures and to assess if 6MWT predicts re-hospitalization.  
Albumin identified over 91% of our patients as frail, yet it was not predictive of 
30 day readmission. It is not a good indicator of frailty in patients with advanced HF 
undergoing LVAD implantation. It is well understood that patients with heart failure 
often have cardiac cachexia so the likelihood of unintentional weight loss is prevalent in 
most of the population reaching end stage heart failure. As a result, malnutrition is 
inevitable and is associated with postoperative complications, prolonged hospitalizations 
and poor outcomes. Furthermore, hypoalbuminemia, as a marker of malnutrition, is 
associated with morbidity and mortality and low albumin levels (<2.5 mg/dl) are 
associated with mortality and morbidity after LVAD implant. In addition, pro-longed 
post-operative length of stay is also associated with low albumin levels.   
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To my knowledge this is the first study to compare these measures of frailty in 
patients with LVADs. Identification of patients at high risk for functional decline and 
poor outcomes is crucial when considering LVAD and patient selection is important to 
attain a favorable outcome. One of the most difficult challenges is differentiating between 
underlying conditions such as inflammatory, malnutrition, low activity levels that can 
occur with both frailty and heart failure.  
There are some limitations that should be acknowledged in the interpretation of 
the present data. This was a single-center study and the results may not be generalizable 
to other patients at other centers. The number of patients in the study was small and we 
were limited in the number of factors we could adjust for in the analysis. Heterogeneity 
among groups of patients should be considered in future research and indicate which 
fraction of patients are bridge to transplant versus destination therapy. Patients considered 
for destination LVAD tend to be older and have more comorbid illnesses. Future research 
should also focus on broader range of outcomes and include a larger sample size. In 
addition, future research should focus on additional predictors of frailty and interventions 
or changes in management that will improve frailty prior to LVAD implantation.  
Conclusion 
Changes associated with the disease process of patients with end stage heart 
failure undergoing LVAD implantation makes it difficult to identify markers of frailty in 
this population. The findings of our study indicate that none of the markers are good 
predictors of frailty in patients with advanced heart failure with LVADs because they all 
identify a vast majority of the patients as frail. Given these findings, it may be more 
beneficial to focus on which measures of frailty improve post-implantation.  
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Table 3.1: Patient demographic and clinical characteristics N = 23 
Characteristics Mean ± SD or N (%) 
Sociodemographics  
Age, years 59.61 ± 9.58 
Gender 
    Male 
    Female 
 
21 (91.3) 
2 (8.7) 
Marital stats 
    Married or cohabiting 
    Living with other family 
 
22 (95.7) 
1 (4.3) 
Readmitted within 30 days 
     No Readmitted 
     Readmitted 
 
16 (69.6) 
7 (30.4) 
Clinical Characteristics  
Body mass index, m2/kg 29.22 ± 5.70 
6 minute walk, meters 189.04 ± 84.163 
Albumin, mg/dl 2.75 ± 0.43 
Etiology of Heart Failure 
     Non-ischemic cardiomyopathy 
     Ischemic cardiomyopathy 
 
8 (34.8) 
15 (65.2) 
Coronary artery disease (CAD) 
     Do not have CAD  
     Have CAD 
 
7 (30.4) 
16 (69.6) 
Diabetes mellitus (DM) 
     Do not have DM 
     Have DM 
 
10 (43.5) 
13 (56.5) 
Chronic kidney disease (CKD) 
     Do not have CKD 
     Have CKD 
 
 
12 (52.2) 
11 (47.8) 
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Table 3.2: Comparison of Left Ventricular Assist Device Patient Characteristics Between 
Patients Readmitted Within 30 Days and Those not Readmitted, N = 23 
Characteristics Not Readmitted, n = 
16 
Mean ± SD or N 
(%) 
Readmitted, n = 
7 
Mean ± SD or N 
(%) 
P 
Sociodemographics 
Age, years 59.7 ± 10.8 59.4 ±6.7 0.95 
Gender 
    Male 
    Female 
 
15 (93.8) 
 1 (6.3) 
 
6 (85.7) 
1 (14.3) 
 
0.56 
Marital stats 
    Married or cohabiting 
    Living with other family 
 
15 (93.8) 
 1 (6.3) 
 
7 (100) 
0 
 
0.39 
 
Clinical Characteristics 
Body mass index, m2/kg 30.2 ± 4.7 26.9 ± 7.5 0.20 
Albumin, mg/dl 2.75 ±.50 2.76 ± .21 0.97 
6 minute walk, meters 177.1  ± 74.6 216.3 ± 104 0.31 
Non-ischemic 
cardiomyopathy 
7 (47.8) 1 (14.3) 0.15 
Coronary artery disease 10 (62.5) 6 (85.7) 0.24 
Diabetes mellitus 8 (50.0) 5 (71.4) 0.33 
Chronic kidney disease 11 (68.8) 0 (0) 0.001 
 
Frailty Characteristics 
Fried Criteria, yes frail 14 (87.5) 6 (85.7) 0.91 
Short Performance Physical 
Battery, yes frail 
11 (68.8) 3 (42.9) 0.25 
Hand grip, yes frail 11 (68.8) 1 (14.3) 0.01 
Albumin, yes frail 14 (87.5) 7 (100) 0.22 
6 minute walk test, yes frail 16 (100.0) 5 (71.4) 0.02 
Low physical activity, yes 
frail 
15 (93.8) 6 (85.7) 0.55 
Gait speed, yes frail 12 (75.0) 4 (57.1) 0.40 
Weight loss, yes frail 10 (62.5) 5 (71.4) 0.68 
Balance, yes frail 10 (62.5) 3 (42.9) 0.38 
Chair sit to stand, yes frail 11 (68.8) 5 (71.4) 0.90 
Self-reported exhaustion, 
yes frail 
16 (100) 7 (100) n/a 
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Table 3.3: Categorization of Left Ventricular Assist Device Patients as Not Frail or Frail 
for Each Individual Frailty Measure, N = 23 
Measure Not frail 
N (%) 
Frail 
N (%) 
Fried Criteria 3 (13) 20 (87) 
Short Performance Physical Battery 9 (39.1) 14 (60.9) 
Hand grip 11 (47.8) 12 (52.2) 
Albumin 2 (8.7) 21 (91.3) 
6 minute walk test 2 (8.7) 21 (91.3) 
Low physical activity 2 (8.7) 21 (91.3) 
Gait speed 7 (30.4) 16 (69.6) 
Self-Reported exhaustion 0 23 (100) 
Weight loss 8 (34.8) 15 (65.2) 
Balance 10 (43.5) 13 (56.5) 
Chair sit to stand 7 (30.4) 16 (69.6) 
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Table 3.4: Frailty Predictors of 30 day Readmission 
 B Odds Ratio 95% 
Confidence 
Interval 
P 
Fried’s Criteria -.154 .857 .065-11.357 .91 
SPPB -1.076 .341 .055-2.131 .250 
Handgrip -2.580 .076 .007-.807 .033 
Albumin .040 1.041 .126-8.598 .970 
6MWT 0.006 1.006 .995-1.017 .304 
Legend: Short Physical Performance Battery (SPPB), Six Minute Walk Test (6MWT) 
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Chapter Four: Factors of Frailty That Improve Post VAD 
Abstract 
Background:  Frailty has been identified as a prognostic marker for adverse 
outcomes in patient with heart failure and patients undergoing cardiac intervention and 
surgery. There is minimal information regarding outcomes and short-term improvement 
in frailty post Left Ventricular Assist Device (LVAD) implantation. Three objective 
measures that reflect frailty and that have been used by others to measures frailty in 
patients with heart failure but not in LVAD patients or to predict outcomes include 
handgrip strength, the six minute walk test (6MWT) and serum albumin. Thus, we chose 
these three measures to reflect frailty and the purpose of the study was to determine 
whether frailty measures improve 3 months post LVAD implantation and to compare 
sensitivity of these three measures to change in frailty.  
Methods: This was a 3 month longitudinal cohort study of 23 patients with 
advanced heart failure who underwent LVAD implantation. Patients were enrolled 
between January 2015 to May 2016 and within 1 week of scheduled date of LVAD 
implantation.  Patients of all ages and implantation strategy were included. Frailty was 
reflected by handgrip strength, 6MWT and serum albumin.  
Results:  Prior to LVAD implantation, frailty measurements by handgrip strength 
identified 12 patients as frail compared to 22 patients by 6MWT and 21 patients by 
albumin. Post LVAD measurements of frailty identified 13 as frail by handgrip, 11 by 
6MWT and 9 by albumin. There was no difference in handgrip strength from pre-
implantation and post-implantation. Only 8% of patient walked 300 meters or more in 6 
minutes prior to LVAD implantation. In contrast, 53% of patients were able to walk more 
80 
 
than 300 meters at 3 months post-implantation with an average 47% improvement in 
6MWT distance (p = 0.002). Mean distance walked increased significantly from pre- to 
post-implantation (p < 0.001). Pre-operatively 21 (91.3%) patients met criteria for frailty 
based on serum albumin cut-point and post-operatively 9 (39.1%) met frailty criteria (p = 
0.002).  Mean serum albumin increased significantly pre- to post-implantation (p < 
0.001). 
Conclusion: In patients with heart failure who undergo LVAD implantation, the 
6MWT and serum albumin measurements are reflect short-term improvement in frailty 
and these simple measures may be used to determine those patients who are responsive to 
LVAD implantation. Frailty by select markers is likely to improve in most people after 
LVAD implantation, and thus frailty should not preclude candidate selection for an 
LVAD.  
Introduction 
Heart failure is a progressive condition that affects 5.7 million Americans with 
more than 670,000 new cases each year.  Approximately 100,000 patients with heart 
failure  in the United States are unresponsive to maximal medical therapy resulting in 
further deterioration, rehospitalization, and death.  The high rate of morbidity and 
mortality, and poor quality of life associated with heart failure has led to exploration of 
additional treatments for those with advanced heart failure that include left ventricular 
assist devices (LVADs).  
Despite improvement in morbidity and mortality with LVADs, multiple 
complications such as stroke, bleeding and device-related infections occur. The cost 
associated with these treatments is extensive. , , ,   Consequently, it is crucial to identify 
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patients who are most likely to benefit from a LVAD. One potential factor that may be 
important to patient selection is frailty.  
Frailty has been identified as a prognostic marker for adverse outcomes including 
death, disability and rehospitalization in patient with heart failure and patients undergoing 
cardiac intervention and surgery., , , , ,  Frailty reflects physiological changes across many 
organ systems due to a decrease in physiological reserve and to vulnerability caused by 
physical and psychological stressors such as acute or chronic illness. When exposed to 
stressors, patients who are frail are at risk for further decompensation, adverse events, 
complications, longer recovery, functional decline and mortality. , , ,   
Frailty in the elderly community and in patients undergoing cardiac surgery leads 
to adverse outcomes and increased mortality and morbidity.,, , ,  Recently, there has been a 
growing interest in the effect of frailty on patients undergoing LVAD. Frailty is prevalent 
in 21% of patients with advanced heart failure who undergo LVAD implantation and is 
associated with increased hospital length of stay, higher risk of hospital readmission and 
increased hospital length of stay.   
Little is known about frailty in patients with an LVAD and most of the research 
has focused on how frailty may impact prognosis and outcomes after LVAD 
implantation. There is minimal information regarding short-term improvement in frailty 
post LVAD implantation. Clarification of how frailty improves post LVAD will allow for 
better patient selection to ensure that those undergoing LVAD implantation benefit from 
the device with minimum complications and are most likely to recover. It typically takes 
approximately 3 months for patients to recover from post-surgical changes, undergo 
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rehabilitation, and adapt to their new lifestyle. Further information is warranted to 
determine if short-term measures in frailty improve during this time frame also. 
 To date, there is no gold standard definition of frailty. In order to attempt to 
operationalize the definition of frailty, Fried proposed a clinical phenotype which defines 
frailty as meeting three out of five phenotypic criteria: 1) slowness; 2) unintended weight 
loss; 3) inactivity; 4) exhaustion; and 5) decreased grip strength.,, The subjectivity of 
some of these indicators and their universality among individuals with advanced heart 
failure suggest that use of Fried’s criteria may be inappropriate with patients with end-
stage heart failure.  Three objective measures that reflect frailty and that have been used 
by others to measures frailty in patients with heart failure but not in LVAD patients or to 
predict outcomes include  handgrip strength, the six minute walk test (6MWT) and serum 
albumin. Thus, we chose these three measures to reflect frailty and the purpose of the 
study was to determine whether frailty measures improve 3 months post LVAD 
implantation and to compare sensitivity of these three measures to change in frailty.  
Methods 
This was a 3 month longitudinal (from one week pre-implant to 3 months post 
LVAD implant) cohort study of 25 patients with advanced heart failure who underwent 
LVAD implantation.  
Subjects 
Patients were enrolled between January 2015 to May 2016 at a major medical 
center and within 1 week of scheduled date of LVAD implantation.  Patients of all ages 
and implantation strategy (i.e., bridge to transplant or destination therapy) were eligible 
for the study if they (1) had a physician diagnosis of advanced heart failure as 
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documented in the hospital medical records with a confirmed left ventricular ejection 
fraction (LVEF) < 25% by echocardiography and (2) were able to complete required 
physical tests (i.e., handgrip strength and 6MWT). A total of 25 eligible patients agreed 
to participate in the study during the enrollment period. One patient was physically 
unable to perform the 6MWT at 3 months post-implantation and one patient died prior to 
3 month follow-up resulting in a final sample of 23 patients.  
Measures 
Frailty was reflected by handgrip strength, 6MWT and serum albumin.  
 Handgrip strength.   Handgrip strength was measured in the dominant hand using 
a hydraulic hand dynamometer by Jamar Hydraulic Hand Dynamometer (JLW 
Instruments, Chicago, IL). The patient was permitted to stand or sit with arms at their 
side not touching their body and elbow bent slightly. They were instructed to squeeze the 
dynamometer with as much force as possible for five seconds. Handgrip strength was 
recorded as the average force to the nearest kilograms of 3 trials spaced 30 seconds apart 
to avoid muscle fatigue. Patients whose handgrip force was < 25% of their body weight 
in kilograms were categorized as frail. The pre-LVAD handgrip strength was measured 
by a nurse practitioner in the patient’s hospital room within 1 day of LVAD implantation. 
Post- LVAD handgrip strength was measured in the clinic room at each patients’ 3 month 
routine follow-up visit by the same nurse practitioner. 
Six minute walk test.  Patients were instructed to walk down a hallway free of 
obstacles at a comfortable pace for 6 minutes. They were permitted to use a walker or 
cane if needed and take rest break although timing continued. To improve accuracy of 
measured distance, 100 meters of the hallway was marked in 1 meter intervals. A stop 
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watch was used to time the test. The total distance walked after 6 minutes was 
documented. Patients walking < 300 meters were categorized as frail. The 6MWT was 
conducted by a nurse practitioner or physical therapist. The pre-LVAD implantation 
6MWT was conducted in a hospital hallway. The post LVAD implantation 6MWT was 
conducted in the clinic hallway at the 3 month routine follow-up visit.  
Albumin. Blood for serum albumin levels was collected as part of the patients’ 
routine pre-operative laboratory work and as part of their routine 3 month post-
implantation laboratory work. Serum was analyzed in the clinical laboratory.  Patients 
were classified as frail if they had an albumin level < 3.5 g/dl. 
Procedure 
Approval to conduct the study was received from the Institutional Review Board. 
Patients admitted for LVAD implantation were recruited for the study by the advanced 
heart failure team. The nurse practitioner for the team explained the study to patients and 
asked them to participate in the study. If they agreed, the nurse practitioner obtained 
written consent while the patient was in the hospital prior to LVAD implantation. 
Demographic and clinical data were retrieved from hospital medical records at baseline 
and 3 months post LVAD implantation. These data were age, gender, albumin, body 
mass index (BMI in kg/m2), etiology of cardiomyopathy (ischemic vs non-ischemic), 
living arrangements and comorbidities (i.e., coronary artery disease [CAD], diabetes 
mellitus [DM] and chronic kidney disease [CKD]). Heart failure related data included 
diagnosis documented by physician from echocardiogram with LVEF < 25%. The 
6MWT and handgrip were measured at baseline and at 3 months post LVAD 
implantation per study protocol.  
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Data Analysis 
Demographic and clinical characteristics were reported using frequencies and 
percentages for categorical variables and mean ± standard deviation for continuous 
variables. Frequencies were used to determine frailty for each measure. Paired t-tests 
were used to determine differences between pre- and post- 6MWT, handgrip strength, 
and serum albumin levels. McNemar’s chi-square tests were used to compare proportions 
of individuals within each frailty category from pre- to post-implantation.  
Results 
Patient characteristics.  The majority of patients were male (88%), over 40% were 
under the age of 60 years, and 96% were married or cohabitating (Table 4.1). The body 
mass index range was 16 kg/m to 44 kg/m pre-implant compared to 20 kg/m -39 kg/m 
post-implant. Only one patient was underweight with a BMI less than 20 kg/m prior to 
LVAD implant. Over 60% of patients had a BMI > 30 kg/m pre-operatively. Post-
operatively 58% had a BMI > 30 kg/m and no patients had a BMI < 20 kg/m. The 
primary etiology of heart failure for this population was ischemic cardiomyopathy (60%). 
The most common comorbidity was CKD (52%), followed by DM (40%) and CAD 
(36%).  
Frailty measures. Frequencies of each frailty measure are listed in Table 4.2. Prior 
to LVAD implantation, frailty measurements by handgrip strength identified 12 patients 
as frail compared to 22 patients by 6MWT and 21 patients by albumin. Post LVAD 
measurements of frailty identified 13 as frail by handgrip, 11 by 6MWT and 9 by 
albumin. Comparison of pre-implantation and 3 month post-implantation frailty measures 
are listed in Table 4.2. There was no difference in handgrip strength from pre-
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implantation and post-implantation. Only 8% of patient walked 300 meters or more in 6 
minutes prior to LVAD implantation. In contrast, 53% of patients were able to walk more 
than 300 meters at 3 months post-implantation with an average 47% improvement in 
6MWT distance (p = 0.002). Mean distance walked increased significantly from pre- to 
post-implantation (p < 0.001). Pre-operatively 21 (91.3%) patients met criteria for frailty 
based on serum albumin cut-point and post-operatively 9 (39.1%) met frailty criteria (p = 
0.002).  Mean serum albumin increased significantly pre- to post-implantation (p < 
0.001). 
Discussion 
Using three single objective markers for frailty, we identified two markers 
sensitive to improvement after LVAD implantation. Both serum albumin and 6MWT 
improved significantly from pre-implantation to 3 months after LVAD implantation.  
There was no change in handgrip strength at 3 months after LVAD implantation.  Alone 
or together these two markers could be used to determine improvement in frailty after 
LVAD implantation. These objective markers have advantages over self-reported 
markers, such as exhaustion and physical activity, that are commonly used to reflect 
frailty and that are subject to patient bias in reporting. Other, longer measures such as 
Fried’s criteria are longer and can over-identify frailty. 
Although there is no gold standard to measure frailty in patients undergoing VAD 
implantation, it is important to assess for frailty in the patient selection process and assess 
for improvement in frailty post implant because of increased risk of post-operative 
complications, and increased morbidity and mortality with frailty. Our findings on frailty 
measures that improve post-LVAD implantation are consistent with those of prior studies 
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in which an improvement in 6MWT was found. Albumin levels have not been used as 
markers of frailty, but has been found to predict outcomes. Our findings suggest serum 
albumin may also be useful as a marker of frailty. 
Hypoalbuminemia is a prognostic indicator in patients with heart failure and is 
associated with poor prognosis after LVAD surgery. , ,   Low albumin levels are reported 
to be present in patients with heart failure but are most prevalent in patients with end 
stage heart failure who are undergoing LVAD implantation. 2, , , , , Our study findings 
were similar to previous studies concluding  91% of patients having low albumin levels 
prior to LVAD implantation and significant improvement in serum albumin levels post 
LVAD implantation. This is consistent with previous findings that report improvement in 
serum albumin levels post-LVAD implantation. Guvenc, et al  (2107) supported that low 
albumin levels are corrected within six months after LVAD implantation and Go et al 
(2015) reported improvement in serum albumin in 94% of patients post LVAD at 1 year.  
Patients in our study had improvement in serum albumin levels 3 months after LVAD 
implantation suggesting that frailty as measured by serum albumin normalized in a 
majority of patients. 
We used the 6MWT based on findings from others studies of 6MWT and frailty. 
Boxer et al. (2010) noted a high correlation between the 6MWT and frailty (as defined by 
Fried Criteria) in patients with heart failure. In a recent study, Hasin et al. (2017) reported 
that the 6MWT was the strongest predictor of post LVAD survival.  Hasin et al. (2012) 
assessed frailty by  6MWT, and their study did show an improvement in 6MWT after 
LVAD implantation at 3 months but approximately 20-30% of patients in their study 
failed to improve. In addition, they measured frailty at 3 months and 1 year and noted that 
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after 3 months patients remained stable with very little improvement at 1 year. Our study 
is consistent with these findings and we found that the 6MWT improved in 50% of 
patient by 3 months.   
In our study, handgrip strength did not change from baseline to 3 months post 
LVAD implantation. Chung et al. (2014) studied monthly handgrip strength from 
baseline to 36 months after LVAD implantation. They saw improvement at 3 months that 
was sustained at 6 month where it plateaued. Our failure to show an improvement at 3 
months may have been a result of our smaller sample size or the fact that 3 months seems 
to be the point at which handgrip strength begins markedly improving. These findings 
suggest that handgrip strength measured at 3 months may not be a good short-term 
marker,    
This study has several limitations. It was a single-center study with a small study 
cohort.  Because the cohort studied was homogenous, this limits generalizability to a 
larger, more diverse population of patients undergoing LVAD implantation. The short 
term nature of the study does not allow any conclusions regarding long-term 
improvement in frailty.  
Conclusion 
In patients with heart failure who undergo LVAD implantation, the 6MWT and 
serum albumin measurements reflect short-term improvement in frailty and these simple 
measures may be used to determine those patients who are responsive to LVAD 
implantation. Frailty by select markers is likely to improve in most people after LVAD 
implantation, and thus frailty should not preclude candidate selection for an LVAD.  
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Table 4.1: Patient Demographic and Clinic Characteristics, n = 23 
Characteristic N (%) or mean ± SD 
 
Age, years 59 ±9.4 
Sex 
      Male 
      Female 
 
21 (91.3) 
2 (8.7) 
Marital status 
      Married 
      Not Married 
 
22 (91.3) 
1 (4.3) 
Body Mass Index, m2/kg 
      Pre-Implantation 
      Post-Implantation 
 
29.2±5.7 
29.9 ±4.9 
Etiology 
      Ischemic 
      Non-ischemic 
 
15 (65.2) 
8 (34.8) 
Comorbidities 
      Coronary Artery Disease 
      Diabetes 
      Chronic kidney  Disease 
LVAD for destination 
therapy 
       
 
16 (69.6) 
13 (56.5) 
11 (47.8) 
15 (65.2%) 
 
 
Table 4.2: Comparison of Pre-Implantation and Post-Implantation Frailty Measures 
Frailty Measure Pre-operative  
mean ± SD 
Post-operative 
mean ± SD 
p-value 
    
Handgrip Strength (kg) 22.8 ± 10.7  24.7 ± 11.1 0.060 
          Frail, n (%) 12 (52.2%) 13 (56.5) 1.00 
Six Minute Walk 
(meters) 
186 ±83.2 275 ± 121.1 <0.001 
          Frail, n (%) 22 (95.7%) 11 (47.8%) 0.002 
Albumin (g/dl) 2.7 ± .4 3.5 ±.4 <0.001 
         Frail, n (%) 21 (91.3%) 9 (39.1%) 0.002 
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Chapter Five: Summary and Integration 
 The overall purpose of this dissertation was to determine which measures of 
frailty were most likely to predict frailty in patients with end stage heart failure who were 
undergoing LVAD implantation and to determine if measures of frailty improved post 
LVAD implantation. The studies were conducted for the following aims: 1) determine 
which measures of frailty measure frailty in patients with LVAD  2) determine if 
measures of frailty improved post LVAD implantation 3) determine which measures of 
frailty are predictive of 30 day readmission.  
Frailty is an emerging concept that has gained interest over the last 30 years. 
Initially, clinicians and researchers started examining frailty in older adults and for the 
past decade, frailty has been an upcoming topic across many spectrums of disease, 
especially in the field of cardiovascular medicine. Due to conflicting ideas about the 
definition of frailty, researchers started focusing on recognition and relationship of 
attributes between aging, disability and chronic disease in hopes of conceptualizing 
frailty.  
After a joint effort between multiple investigators, a general agreement described 
the core definition of frailty as an “increase vulnerability to stressors due to impairments 
in multiple, inter-related systems that lead to a decline in homeostatic reserve and 
resilience.” This definition served as a foundation to explore distinct concepts and ways 
to measure and distinguish frailty from deterioration due to chronic disease.  Although an 
agreement on the main core of frailty was established, a comprehensive definition was 
lacking. Unique characteristics of frailty that spread across a continuum of frailty 
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remained in question, especially when establishing criteria and the most commonly used 
measures to label one as frail.  
In an attempt to conceptualize frailty, Fried established 5 criteria to measure 
frailty. The Cardiovascular Health Study validated the construct validity of these five 
measures which include weight loss, weakness, exhaustion, slowness, and low activity. 
Fried’s criteria is the most commonly used measure of frailty for most populations in 
current research. However, most research validating Fried’s criteria has been conducted 
in older, aging adults and not in populations with chronic disease so the validity in these 
populations remains uncertain. Due to the severity of illness, overlap of physiological 
responses and decrease in physical function associated with chronic disease, the question 
of applicability of Fried’s criteria to patients with chronic heart failure remains.  
Subsequently, this leads to the exploration of other measures that may be more 
appropriate and easier to administer or measure in this population.  
Patients with end stage heart failure suffer from physical deterioration, 
malnutrition and chronic inflammatory response which all overlap with components of 
frailty. Research has demonstrated that patients with HF who are frail are more likely to 
die or have adverse outcomes compared to those without frailty. Given the mortality rates 
of those with end stage heart failure, advanced therapies including surgical options are on 
the rise for treatment. 
Chapter two discusses the epidemiology and pathophysiology of heart failure and 
surgical approaches for those with end stage heart failure. As discussed, heart failure 
continues to increase in both incidence and prevelance and 5 year mortality is 80%.  
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Heart failure is most common cause of re-hospitalization and is related to symptoms 
caused by congestive exacerbations. Guideline directed therapy is essential to treating 
heart failure but for those who are refractory to medication therapy surgical approaches 
including heart transplant or LVADs are available to those who are candidates.  
Heart transplant remains the gold standard with a 1 year survival rate of 90%. 
Approximately 3500 heart transplants are performed annually in the United States.  The 
most common cause of post-transplant complications is early graft failure which can lead 
to death. With advancements in immunosuppression, acute rejection rates trend 
downward. Long term complications are mostly related to cardiac allograft vasculopathy 
in addition to malignancy.  
Despite promising results with heart transplantation, challenges remain due to a 
shortage of donor organs in comparison to those listed. The use of mechanical circulatory 
support, including LVADs, emerged and is used to offer patients an option for destination 
therapy or bridge to transplant pending candidacy. Initially, pulsatile pumps were used as 
a bridge to transplant and noted a 48% reduction in mortality compared with optimal 
medical therapy. Durability of pulsatile pumps was an issue and continuous flow pumps 
evolved. A recent analysis of the INTERMACS registry revealed an 89% 1 year survival 
rate with the use of continuous flow pumps.  
Due to the increasing number of patients with advanced heart failure, the current 
strategy for screening patients for heart transplantation and LVAD is gaining acceptance. 
Regardless of which surgical option is decided upon, the benefits of transplant and 
ventricular assist devices outweighs pharmacological treatment for heart failure alone.  
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Frailty impacts outcomes in patients undergoing cardiac surgery and should be 
identified in patients with advanced heart failure undergoing surgical options, especially 
those undergoing LVAD.  It is important to recognize those who are frail and those more 
likely to benefit from LVAD and have positive outcomes. Recent studies have 
demonstrated that patient selection is essential to ensure positive results with less adverse 
events following LVAD implantation. However, in order to recognize those who will 
most likely benefit, more research is needed to determine the best way to select these 
candidates.  Identifying those who are frail, is gaining interest for patient selection and 
while frailty has been extensively studied in other populations, limited research has been 
conducted in patients undergoing LVAD. 
Chapter three is a data analysis on measures of frailty in patients with LVADs and 
identifies measures of frailty in patients with heart failure scheduled for LVAD 
implantation and which measures of frailty are predictive of 30 day readmissions.  I 
identify a subset of 23 patients with end stage heart failure enrolled in a study at a 
university medical center. Baseline measures of Fried’s criteria (gait speed, exhaustion, 
weight loss, strength, physical activity), albumin, 6 MWT, handgrip and SPBB were 
entered into the model along with covariates identified from the literature (age, gender, 
BMI, heart failure etiology, diabetes, coronary artery disease and chronic kidney disease).  
Demographic and clinical characteristics were reported using frequencies and 
percentages for categorical variables and mean ± standard deviation for continuous 
variables. Frequencies were used to determine frailty for each measure. Chi-square 
analysis was used to determine if the measures of frailty were predictive of 30 day 
readmission. All analysis was conducted using SPSS software.  
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The study concluded that none of the markers examined were good predictors of 
frailty in patients with advanced heart failure with LVADs. The only marker that was 
predictive of 30 day readmission rates was handgrip strength. This was a negative 
association indicating that compared to not frail, frail patients by handgrip criteria were 
93.4% less likely to be admitted. Over 85% of the patients were frail as measured by 
Fried’s criteria, 6MWT, Low Physical Activity, Self-reported exhaustion, and albumin. 
The other markers of frailty measured frailty in over 50% of the patients. These findings 
indicate that these measures of frailty are not precise measurements of frailty and some 
markers such as self-reported exhaustion may be overly sensitive to measuring frailty in 
patients with LVADs.  
The results from my study may be due to the fact that measures of frailty such as 
Fried’s and SPPB  that are devised of several components that  may not accurately 
identify frailty  in patients with end stage heart failure with LVADs because some of 
these components may be influenced by chronic disease. Chronic inflammation which is 
associated with heart failure is also a linked to cognitive impairment which affects 
physical performance measure such as gait speed which is a part of both the Fried’s and 
SPBB criteria.  In addition, our study did not recognize hand grip strength as a measure 
of frailty, whereas other studies have found that hand grip strength is an independent 
predictor of frailty. Our small sample size is likely the culprit to the difference in these 
findings. In addition, discrepancies may be attributed to the degree of illness in the 
cohort. Some patients were severely ill requiring more emergent LVAD implantation, 
while others were stable at home and scheduled for LVAD implantation.  
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Once measures of frailty have been identified, it is important to determine which 
measures may improve over time after an intervention.  Previous findings support that 
those who have improvement in measures of frailty, have fewer complications and better 
outcomes. To further expand on this concept, we examined which measures of frailty 
improved over time after LVAD implantation. 
Chapter Four is an analysis of albumin, 6MWT and handgrip and whether these 
measures of frailty improve over 3 months. Longitudinal data was collected at baseline 
(pre-implantation) and at 3 months (post-implantation). Data from 23 patients with HF 
who underwent LVAD implantation was used in the analysis. Demographic and clinical 
characteristics were reported using frequencies and percentages for categorical variables 
and mean ± standard deviation for continuous variables. Frequencies were used to 
determine frailty for each measure. Paired t-tests were used to determine differences 
between pre- and post- 6MWT, handgrip strength, and serum albumin levels. McNemar’s 
chi-square tests were used to compare proportions of individuals within each frailty 
category from pre- to post-implantation. Results of the study demonstrated the 6MWT 
and albumin improved post LVAD implantation at 3 months while handgrip strength did 
not change.   
Our findings on frailty measures that improve post-LVAD implantation are 
consistent with prior studies who have examined improvement in 6MWT and albumin 
levels prior and post implantation but differ from previous investigations regarding frailty 
as defined by handgrip strength.  Again, our small sample size likely contributes to the 
difference in findings regarding handgrip strength. Also, longitudinal studies have the 
ability to demonstrate progress and change over time. Chung et al found that handgrip 
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was an independent predictor of frailty, but their study measured changes in handgrip 
over 6 months. Additionally, Maurer et al reported that is took at least 3 months to start 
seeing improvement in frailty with significant improvement at 6 months. We only 
compared 2 time points which included baseline and 3 months post implantation. Based 
on previous the previous finding, more long term follow-up is needed  to identify 
reversibility of frailty.  
Impact of Dissertation on the State of Science 
This dissertation represents an important contribution to the literature as little is 
known about frailty in patients with LVADs. The findings of this dissertation filled some 
gaps in understanding which measures of frailty including Fried’s criteria, SPPB, 
albumin, 6MWT and handgrip strength measured frailty in patient with end stage HF 
undergoing LVAD implantation and which measures of frailty predict 30 day 
readmission. In addition, the findings support which measures of frailty improve post 
LVAD implantation.  
Fried’s criteria is the most commonly used frailty measure in patients with 
LVADs and is highly predictive of adverse outcomes. Multidimensional frailty measures 
such as Fried’s criteria, include multiple domains that may vary from one measure to 
another and may be difficult to apply in certain settings and in patients that are severely 
ill. Single item measures may be successful in measuring frailty and may be more 
practical in patients with LVADs. While several studies have examined gait speed as a 
single measure and a couple of studies have examined handgrip as a single measure, 
other specific measures that can help identify frailty are unknown.  
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In Chapter three, I evaluate if single measures of frailty and measurement tools 
that utilize several components to measure frailty measure frailty in patients with LVADs 
and if these markers of frailty predict 30 day readmission rates. No studies in the 
literature evaluating frailty have examined all these tools and no studies have looked at 
frailty measures that predict 30 day readmission rates. Prior studies have examined how 
frailty impacts length of stay, time to extubation and adverse outcomes but the results are 
inconsistent. Whether single objective measures of frailty are valid in determining frailty, 
more research is needed but my study findings provide a strong beginning foundation.   
Additionally, prior studies that measure frailty in older adults have demonstrated 
that some measures of frailty can improve. Very few studies have examined this in 
patients with LVADs. There are limited longitudinal studies examining the reversal of 
frailty measures in patients receiving LVADs Improvement in frailty measures after 6 
months has been examined by some investigators but specific measures that support 
reversibility of frailty are unknown. Improvement in handgrip strength and gait speed 
post LVAD implantation has been investigated. Additional measures of frailty in patients 
with LVADs that support reversibility of frailty have not been examined.  
The results described in chapter 4 advances the state of science in evaluating how 
baseline measures of albumin, 6MWT and handgrip strength improve from baseline to 3 
months. My study supports that albumin and 6MWT improved 3 months post LVAD. 
While handgrip strength did not improve at 3 months, other investigators found that at 6 
months, handgrip strength did improve and more long-term analysis should be considered 
in future studies.  
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Recommendations for future research 
Frailty is an important predictor of adverse outcomes in patients with HF 
undergoing LVAD such as 30 day readmission, increased hospital LOS, mortality and 
post-operative complications. Frailty is more common in patients with chronic disease 
such as those with end-stage heart failure. As a result, frailty should be routinely assessed 
in patients with end stage heart failure approaching LVAD implantation to detect the 
presence of frailty, need for early intervention to slow the progression and improve 
outcomes and assist with patient selection for LVAD implantation.  
In order to assess the presence of frailty, clinicians need to be able to use sound 
measures that are easy to administer and brief without being burdensome to the patients. 
There are tools available to measure frailty but some measures are lengthy and 
burdensome making it difficult to complete. More studies need to be conducted in order 
to replicate the results of this study and support the reliability in patients with HF 
undergoing LVAD implantation. In addition, measurement tools with multiple 
components may over diagnose frailty whereas single measures may be prone to missing 
frailty. However, the underlying assumption would be that because components of the 
pathologic process of frailty are associated with each other, not all are necessary to be 
labeled as frail and single measures may be adequate. Addition research is needed to test 
this assumption.   
Heart failure is a dynamic illness and future research should focus on long-term 
follow-up to determine how frailty impacts outcomes and which measures of frailty are 
reversed following LVAD implantation. Patients with end-stage heart failure are often 
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deconditioned, malnourished, and have a chronic inflammatory response. Due to their 
condition they may not seek and utilize available resources appropriately such as 
attending cardiac rehabilitation, nutrition counseling, or clinic appointments. As a result, 
their condition further deteriorates and frailty is exacerbated. Focusing on earlier 
identification of frailty in the ambulatory setting and early intervention for physical 
rehabilitation and nutritional supplementation should also be a focus in this population to 
slow the progression of frailty. A small randomized trial found that patients who were 
enrolled in cardiac rehabilitation after LVAD implantation had promising results with 
improvements in frailty. Additional research including longitudinal data are needed to 
further support these findings.  
Limitations 
Limitations of these studies include that these were single-centered studies and 
each of the studies reported in this dissertation had a small sample size. In addition, 
patients with end stage heart failure who underwent LVAD implantation participated in 
the study which limits heterogeneity. Additional potential limitations include the use of 
self-reported measures of exhaustion and physical activity and in some patients self-
reported weight loss in the past year. We did not have access to all patients’ information 
from previous medical records to verify weight loss. Additionally, the fact that many of 
these patients were very ill resulted in limitations of the applicability of some of the 
frailty measures.  The relatively short-term follow-up does not allow any conclusions to 
be made about long-term outcomes and reversibility.  
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There are barriers to engaging in some measures of frailty. Patients who have 
marked physical limitations are unable to complete some measures such as 6 MWT and 
previously reported gait speed test. Utilizing weight loss as a measure of frailty may 
underestimate the prevalence of frailty in obese patients and it is also difficult to discern 
true weight loss in patients with heart failure due to variability secondary to volume 
status. Chronic inflammation associated with chronic disease is also associated with 
cognitive impairment which is associated with a decline in psychomotor activities such as 
gait speed. This may lead to inconsistencies with identifying those who are frail because 
it is often difficult to differentiate between frailty and the effects of the disease itself. 
Conclusion 
In summary, implications of this dissertation include the importance of 
monitoring frailty over time as well as the need for further longitudinal studies that 
examine the relationships between frailty and early intervention to slow the progression 
of frailty. A better understanding how frailty changes over time will allow clinicians the 
opportunity for timely interventions designed to reduce the progression and improve 
outcomes. In addition, identifying those that are frail will allow for better patient 
selection to avoid unnecessary LVAD implantation on those likely to not survive or have 
post-operative complications and adverse events and will identify markers of frailty that 
will likely improve in patients post LVAD implantation.  
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Medical Weight loss 
October 2005 – December Nashville General Hospital Registered Nurse 
2006   Nashville, TN  Emergency Room 
September 2004 – October Vanderbilt University Hospital Registered Nurse 
2005 Nashville, TN  Emergency Room 
June 2003 – August 2004 Lifeline Home Health Physician/Community 
Bowling Green, KY Educator 
January 2002 – May 2003 University of Kentucky Teaching Assistant 
Lexington, KY  Kinesiology 
111
Professional Experience, continued 
Dates  Institution and Location Academic Position 
January 2007 – June 2009 University of Kentucky College Pre-Doctoral 
of Nursing Fellowship 
Lexington, KY 
Awards and Honors 
Cal Turner Leadership Recipient, 2006 
Vanderbilt University Nursing Scholarship, 2005 – 2006 
Publications 
*Falls, Candice, Kolodziej, Andrew (2019). Surgical Approaches in Heart Failure. Critical Care 
Nursing Clinics 907, Volume 31, Issue 3
